documents incorporated reference document part proxy statement annual meeting shareholders held may filed part iii securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients company recently sold certain businesses healthcare services segment process divesting remaining businesses company continues look investment opportunities area health care approach investments shifted toward venture capital investments third parties opposed whollyowned businesses alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded company incorporated new jersey product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners planned spinoff womens health legacy brands biosimilars new company february merck announced intention spinoff spinoff products womens health trusted legacy brands biosimilars businesses new yettobenamed independent publicly traded company newco distribution newcos publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes legacy brands included transaction consist dermatology pain respiratory select cardiovascular products including zetia vytorin well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned newco development capabilities initially focused latestage development lifecycle management expected time develop research capabilities selected therapeutic areas spinoff expected completed first half subject market certain conditions see risk factors risks related proposed spinoff newco table contents product sales total company sales including sales companys top pharmaceutical products well sales animal health products follows millions total sales pharmaceutical keytruda januviajanumet gardasilgardasil proquadmmr iivarivax bridion isentressisentress hd pneumovax nuvaring zetiavytorin simponi animal health livestock companion animals revenues revenues primarily comprised healthcare services segment revenue thirdparty manufacturing sales miscellaneous corporate revenues including revenue hedging activities pharmaceutical pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices certain products within companys franchises follows oncology keytruda pembrolizumab companys antipd programmed death receptor therapy monotherapy treatment certain patients melanoma nonsmallcell lung cancer nsclc smallcell lung cancer sclc head neck squamous cell carcinoma hnscc classical hodgkin lymphoma chl primary mediastinal large bcell lymphoma pmbcl urothelial carcinoma microsatellite instabilityhigh msih mismatch repair deficient cancer gastric gastroesophageal junction adenocarcinoma esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma keytruda also used treatment certain patients combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination axitinib renal cell carcinoma combination lenvatinib endometrial carcinoma emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting addition company recognizes alliance revenue related sales lynparza olaparib oral poly adpribose polymerase parp inhibitor certain types advanced ovarian breast pancreatic cancers lenvima lenvatinib certain types thyroid cancer hepatocellular carcinoma combination everolimus certain patients renal cell carcinoma combination keytruda certain patients endometrial carcinoma vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children vaqta hepatitis vaccine inactivated indicated prevention disease caused hepatitis virus persons months age older table contents hospital acute care bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery noxafil posaconazole prevention invasive fungal infections primaxin imipenem cilastatin sodium antibacterial product invanz ertapenem sodium treatment certain infections cubicin daptomycin injection iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms cancidas caspofungin acetate antifungal product prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipients r allogeneic hematopoietic stem cell transplant immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases remicade infliximab treatment inflammatory diseases company markets europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicated treatment insomnia characterized difficulties sleep onset andor sleep maintenance virology isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection zepatier elbasvir grazoprevir treatment adult patients chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient populations cardiovascular zetia ezetimibe marketed ezetrol countries outside united states vytorin ezetimibesimvastatin marketed inegy outside united states atozet ezetimibe atorvastatin marketed outside united states rosuzet ezetimibe rosuvastatin marketed outside united states cholesterol modifying medicines adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes womens health nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshaped subdermal contraceptive implant animal health animal health segment discovers develops manufactures markets wide range veterinary pharmaceuticals vaccines health management solutions services well extensive suite digitally connected identification traceability monitoring products principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines exzolt systemic treatment poultry red mite infestations slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solutions animal identification monitoring traceability table contents companion animal products bravecto fluralaner line oral topical parasitic control products dogs cats last weeks nobivac vaccine lines flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line horses scalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies discussion sales companys products see item managements discussion analysis financial condition results operations product approvals set forth summary significant product approvals received company product date approval us food drug administration fda approved ervebo prevention disease caused december zaire ebolavirus individuals years age older ervebo european commission ec granted conditional marketing authorization ervebo active november immunization individuals years age older protect ebola virus disease caused zaire ebola virus japanese ministry health labour welfare mhlw approved keytruda three new firstline december indications across advanced renal cell carcinoma rcc recurrent distant metastatic head neck cancer ec approved two new regimens keytruda firstline treatment metastatic unresectable recurrent november head neck squamous cell carcinoma hnscc china national medical products administration nmpa approved keytruda firstline treatment metastatic squamous nonsmall cell lung cancer nsclc november combination chemotherapy keytruda nmpa approved keytruda monotherapy firstline treatment certain patients advanced nsclc october whose tumors express pdl fda approved keytruda plus lenvima combination treatment patients certain types endometrial september carcinoma september ec approved keytruda combination axitinib firstline treatment patients advanced rcc fda approved keytruda recurrent locally advanced metastatic squamous cell carcinoma july esophagus patients whose tumors express pdl combined positive score cps cps disease progression one prior lines systemic therapy table contents june fda approved keytruda monotherapy patients metastatic smallcell lung cancer sclc disease progression platinumbased chemotherapy least one prior line therapy fda approved two indications keytruda firstline treatment patients metastatic june unresectable recurrent hnscc monotherapy patients whose tumors express pdl cps combination platinum fluorouracil regardless pdl expression april fda approved keytruda combination axitinib firstline treatment patients advanced rcc fda approved expanded label keytruda monotherapy firstline treatment patients stage iii nsclc candidates surgical resection definitive chemoradiation metastatic april nsclc whose tumors express pdl tumor proportion score tps determined fda approved test epidermal growth factor receptor egfr anaplastic lymphoma kinase positive alk genomic tumor aberrations keytruda april ec approved new extended dosing schedule keytruda approved monotherapy indications nmpa approved keytruda firstline treatment metastatic nonsquamous nsclc combination april chemotherapy march ec approved keytruda combination chemotherapy firstline treatment adults metastatic squamous nsclc february fda approved keytruda adjuvant treatment patients melanoma involvement lymph nodes following complete resection mhlw approved keytruda five indications including three expanded uses advanced nsclc one january melanoma well new indication advanced microsatellite instabilityhigh tumors fda approved lynparza firstline maintenance therapy patients germline brcamutated december gbrcam metastatic pancreatic cancer whose disease progressed least weeks first line platinumbased chemotherapy regimen december nmpa approved lynparza firstline maintenance therapy brcam advanced ovarian cancer july ec approved lynparza monotherapy maintenance treatment adult patients advanced brcam highgrade epithelial ovarian fallopian tube primary peritoneal cancer lynparza mhlw approved lynparza firstline maintenance therapy patients brcam advanced ovarian june cancer june ec approved lynparza use firstline maintenance therapy patients brcam advanced ovarian cancer april ec approved lynparza treatment gbrcam hernegative advanced breast cancer fda approved supplemental new drug applications sndas pifeltro doravirine combination pifeltro delstrigo september antiretroviral agents delstrigo doravirine lamivudine tenofovir disoproxil fumarate complete regimen use appropriate adults hiv infection virologically suppressed stable antiretroviral regimen table contents fda approved recarbrio imipenem cilastatin relebactam treatment adults complicated recarbrio july urinary tract complicated intraabdominal bacterial infections limited alternative treatment options available ec approved zerbaxa treatment adults hospitalacquired pneumonia including ventilator august associated pneumonia used combination antibacterial agent active grampositive zerbaxa pathogens known suspected contributing infectious process fda approved zerbaxa g dose treatment patients years older hospitalacquired june bacterial pneumonia ventilatorassociated bacterial pneumonia habpvabp bravecto november fda approved bravecto plus topical solution cats indicated external internal parasite infestations july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company wellpositioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances licensing arrangements collaborations refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients table contents backdrop united states enacted major health care reform legislation patient protection affordable care act aca various insurance market reforms since advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also required pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole result balanced budget act effective beginning point service discount increased point service discount coverage gap addition point service discount extended biosimilar products merck recorded reduction revenue approximately million million million respectively related donut hole provision also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion decreased billion expected remain amount fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million million million costs within selling general administrative expenses respectively annual health care reform fee february centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective significant uncertainty future aca particular health care laws general united states company participating debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature repeal replacement aca actions could material adverse effect companys business cash flow results operations financial condition prospects number states passed pharmaceutical price cost transparency laws laws typically require manufacturers report certain product price information financial data state laws also require manufacturers provide advance notification price increases company expects states continue focus pharmaceutical price transparency focus continue exert pressure product pricing company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care organizations federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures example health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls addition congress andor administration may consider proposals allow international reference pricing certain conditions importation medicines countries administration recently proposed draft rule would allow importation certain lowercost prescription drugs canada rule finalized proposed states certain nonfederal governmental entities would able submit importation program proposals fda review authorization twoyear programs opportunity extend two years public comment period proposed rule expire march following comment period fda review finalize table contents proposal states parties submit plans comply federal rule proposed rule adopted likely time states parties actually implement importation plans october administration also issued advance notice proposed rulemaking implement international pricing index ipi model united states products covered medicare part b proposal would reduce medicare part b payments drugs based market basket international prices allow private sector vendors negotiate prices drugs take title drugs compete physician hospital business change physician reimbursement medicare part b current model eliminate buy bill system instead pay physicians based flat fee approximates revenue currently receive drugs public comments ipi proposal accepted late unclear agency may issue proposed rule ipi model adoption one proposed rules could material adverse effect companys business results operations financial condition remains uncertain proposals may included part future federal legislative proposals would directly indirectly affect company us private sector consolidation integration among health care providers major factor competitive marketplace pharmaceutical products health plans pharmacy benefit managers consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments increasingly employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining placement unfavorable pricing could adversely impact revenue addition formulary tier copay differentials private health insurance companies selfinsured employers raising co payments required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product generic product available requiring patient first fail one generic products permitting access branded medicine management tools also used treatment areas payer taken position multiple branded products therapeutically comparable us payer market concentrates drugs become available generic form pharmaceutical companies may face greater pricing pressure private thirdparty payers order provide information companys pricing practices company annually posts website pricing transparency report united states report provides companys average annual list price net price increases average discounts across companys us portfolio dating back companys gross us sales reduced approximately result rebates discounts returns efforts toward health care cost containment also remain intense european countries company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries europe attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys drugs guidelines examining reference pricing usually set local markets changed pursuant local regulations addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occurred occur furthermore government order repricings specific products determines use product exceed certain thresholds defined applicable repricing rules pursuant rules japanese government reduced price keytruda effective february additionally keytruda subject another significant price reduction april provision japanese pricing rules companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys current inline products absence trade impediments adverse pricing controls recent years chinese government introduced implemented number structural reforms accelerate shift innovative products reduce costs since multiple new policies introduced government improve access new innovation reduce table contents complexity regulatory filings accelerate review approval process led significant increase number new products approved year additionally chinese government updated national reimbursement drug list first time eight years mechanism drugs added list evolves inclusion may require price negotiation could impact outlook market selected brands drugs added two pathways direct inclusion price negotiations price negotiations price reductions approximately average required inclusion pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution volume based procurement vbp government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered first two rounds vbp average price reduction expansion vbp program remains seen companys focus emerging markets addition china continued governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets including china certain markets outside united states also implemented cost management strategies health technology assessments hta examples include uk france germany ireland italy sweden hta process procedure according assessment public health impact therapeutic impact economic social impact use given medicinal product national health care system individual country conducted htas generally focus clinical efficacy effectiveness safety cost costeffectiveness individual medicinal products well potential implications health care system elements medicinal products compared treatment options available market outcome htas often influence pricing reimbursement status granted medicinal products regulatory authorities individual european union eu member states negative hta one companys products leading recognized hta body could undermine companys ability obtain reimbursement product eu member state negative assessment issued also eu member states hta procedures require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement united states htas also used government private payers beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability changes trade sanctions embargoes significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes wellpositioned respond evolving health care environment market forces pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement table contents particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation accelerated regulatory review process medicines designation fda also undertaken efforts bring generic competition market efficiently timely manner eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states particular eu regulators may approve products subject number postauthorization conditions examples typical postauthorization commitments include additional pharmacovigilance conduct clinical trials establishment patient registries physician patient education controlled distribution prescribing arrangements noncompliance postauthorization conditions pharmacovigilance obligations lead regulatory action including variation suspension withdrawal marketing authorizations enforcement regulatory actions including imposition financial penalties companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access medicines vaccines quality health care around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition innovative social investments including philanthropic programs impact investing merck also helping strengthen health systems build capacity particularly underresourced communities merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicines vaccines merck launched merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent grantmaking organization partnered variety organizations dedicated improving global health privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including eu general data protection regulation went effect may imposes penalties global revenue california consumer privacy act became effective january additional laws regulations enacted united states europe asia latin america increased enforcement litigation activity united states developed markets increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving risks certified compliant approved asia pacific economic cooperation crossborder privacy rules system euus swissus privacy shield programs binding corporate rules eu distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy table contents benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term periods patented product regulatory review fda eu also provides additional six months pediatric market exclusivity attached products supplementary protection certificate spc japan provides additional term pediatric studies attached market exclusivity unrelated patent term patent portfolios developed products introduced company normally provide market exclusivity company following key patent protection united states eu japan china including potential patent term extensions pte spcs indicated following marketed products table contents product year expiration us year expiration eu year expiration japan year expiration china emend injection expired na januvia janumet na janumet xr na na isentress simponi na na na lenvima pending pte patents spcs adempas bridion pending pte nexplanon device device marketed bravecto pending pte patents spcs gardasil expired na gardasil patents spcs na keytruda patents spcs lynparza pending pte patents spcs zerbaxa patents spcs pending pte na belsomra na na prevymis pending pte patents spcs na steglatro pending pte patents spcs na steglujan pending pte patents spcs na segluromet pending pte patents spcs na delstrigo pending pte patents spcs na na pifeltro pending pte patents spcs na na recarbrio pending pte na na na notecompound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities na currently marketing approval eu date represents expiration date following five countries france germany italy spain united kingdom major eu markets spc applications filed granted major eu markets patent expiry date spc expiry date listed pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date eligible months pediatric exclusivity company marketing rights us japan china expiration distribution agreement janssen pharmaceuticals inc part global strategic oncology collaboration eisai commercialized worldwide collaboration bayer ag part global strategic oncology collaboration astrazeneca commercialized promoted worldwide except japan collaboration pfizer inc table contents company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us mk gefapixant mk vericiguat v pneumoconjugate vaccine mka islatravirdoravirine developed worldwide collaboration bayer ag unless otherwise noted patents charts compound patents patent may subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program december approximately people employed companys research activities company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing table contents companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases diabetes metabolic diseases infectious diseases neurosciences pain respiratory diseases vaccines development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda table contents order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review addition generating antibiotic incentives act fda may grant qualified infectious disease product qidp status antibacterial antifungal drugs intended treat serious life threatening infections including caused antibiotic antifungal resistant pathogens novel emerging infectious pathogens qualifying pathogens qidp designation offers certain incentives development qualifying drugs including priority review nda filed eligibility fast track designation fiveyear extension applicable exclusivity provisions food drug cosmetic act primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states outside united states eu company submits marketing applications national regulatory authorities examples ministry health labour welfare japan health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia national medical products administration china country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market united states eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review united states internationally keytruda antipd therapy approved treatment many cancers clinical development expanded indications approvals result broad clinical development program currently consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including biliary tract cervical colorectal cutaneous squamous cell endometrial gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma mesothelioma nasopharyngeal nonsmallcell lung ovarian pmbcl prostate renal smallcell lung triplenegative breast urothelial many currently phase clinical development trials planned cancers keytruda review eu monotherapy firstline treatment patients stage iii nsclc candidates surgical resection definitive chemoradiation metastatic nsclc whose tumors express pdl tps egfr alk genomic tumor aberrations based results phase keynote trial table contents keytruda review japan monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma based results pivotal phase keynote trial keytruda also review japan monotherapy secondline treatment advanced metastatic esophageal esophagogastric junction carcinoma based results phase keynote trial merck made decision withdraw type ii variation application keytruda indication eu october fda accepted supplemental bla seeking use keytruda treatment patients recurrent andor metastatic cutaneous squamous cell carcinoma cscc curable surgery radiation based results keynote trial fda set pdufa date june february merck announced fda issued complete response letter crl regarding mercks supplemental blas seeking update dosing frequency keytruda include mg dose infused minutes everysixweeks qw option multiple indications submitted applications based pharmacokinetic modeling simulation data presented american society clinical oncology asco annual meeting data supported ec approval mg qw dosing keytruda monotherapy indications march merck reviewing letter discuss next steps fda additionally keytruda received breakthrough therapy designation fda combination neoadjuvant chemotherapy treatment highrisk earlystage triplenegative breast cancer tnbc combination enfortumab vedotin firstline setting treatment patients unresectable locally advanced metastatic urothelial cancer eligible cisplatincontaining chemotherapy fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints september merck announced results pivotal neoadjuvantadjuvant phase keynote trial patients earlystage tnbc trial investigated regimen neoadjuvant keytruda plus chemotherapy followed adjuvant keytruda monotherapy keytruda regimen compared regimen neoadjuvant chemotherapy followed adjuvant placebo chemotherapyplacebo regimen interim findings presented european society medical oncology esmo congress neoadjuvant phase keytruda plus chemotherapy resulted statistically significant increase pathological complete response pcr versus chemotherapy patients earlystage tnbc improvement seen adding keytruda neoadjuvant chemotherapy observed regardless pdl expression dual primary endpoint eventfreesurvival efs median followup months keytruda regimen reduced risk progression neoadjuvant phase recurrence adjuvant phase compared chemotherapyplacebo regimen merck continues discuss interim analysis data keynote regulatory authorities keytruda breast cancer clinical development program encompasses several internal external collaborative studies february merck announced pivotal phase keynote trial investigating keytruda combination chemotherapy met one dual primary endpoints progressionfree survival pfs patients metastatic triplenegative breast cancer mtnbc whose tumors expressed pdl cps based interim analysis conducted independent data monitoring committee dmc firstline treatment keytruda combination chemotherapy nabpaclitaxel paclitaxel gemcitabinecarboplatin demonstrated statistically significant clinically meaningful improvement pfs compared chemotherapy alone patients based recommendation dmc trial continue without changes evaluate dual primary endpoint overall survival os may merck announced phase keynote trial evaluating keytruda monotherapy second thirdline treatment patients metastatic tnbc meet prespecified primary endpoint superior os compared chemotherapy endpoints formally tested per study protocol primary endpoint os met june merck announced full results pivotal phase keynote trial evaluating keytruda monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma monotherapy arm study keytruda met primary endpoint demonstrating noninferiority chemotherapy current standard care os patients whose tumors expressed pdl cps combination arm keynote keytruda plus chemotherapy found statistically superior os cps cps pfs cps compared chemotherapy alone results presented american society clinical oncology asco annual meeting september fda table contents approved keytruda thirdline treatment previously treated patients recurrent locally advanced metastatic gastric gastroesophageal junction cancer whose tumors express pdl cps determined fdaapproved test keynote potential confirmatory trial accelerated thirdline approval addition keynote additional firstline phase studies mercks gastric clinical program include keynote keynote well keynote neoadjuvant adjuvant treatment setting january merck announced phase keynote trial investigating keytruda combination chemotherapy met one dual primary endpoints pfs firstline treatment patients extensive stage sclc final analysis study also improvement os patients treated keytruda combination chemotherapy compared chemotherapy alone however os results meet statistical significance per prespecified statistical plan results presented upcoming medical meeting discussed regulatory authorities lynparza oral parp inhibitor currently approved certain types advanced ovarian breast pancreatic cancers codeveloped multiple cancer types part collaboration astrazeneca lynparza review eu firstline maintenance monotherapy patients gbrcam metastatic pancreatic cancer whose disease progressed following firstline platinumbased chemotherapy lynparza approved indication fda december based results phase polo trial decision ema expected second half january fda accepted supplemental nda lynparza combination bevacizumab maintenance treatment women advanced ovarian cancer whose disease showed complete partial response firstline treatment platinumbased chemotherapy bevacizumab based results pivotal phase paola trial pdufa date set second quarter indication also review eu january fda accepted priority review supplemental nda lynparza treatment patients metastatic castrationresistant prostate cancer mcrpc deleterious suspected deleterious germline somatic homologous recombination repair hrr gene mutations progressed following prior treatment new hormonal agent based positive results phase profound trial pdufa date set second quarter indication also review eu june merck astrazeneca presented full results phase solo trial evaluated lynparza compared chemotherapy treatment platinumsensitive relapsed patients gbrcam advanced ovarian cancer received two prior lines chemotherapy results trial showed statisticallysignificant clinicallymeaningful improvement objective response rate orr lynparza arm compared chemotherapy arm key secondary endpoint pfs also significantly increased lynparza arm compared chemotherapy arm results presented asco annual meeting mk selumetinib mek inhibitor codeveloped part strategic collaboration astrazeneca selumetinib priority review fda potential new medicine pediatric patients aged three years older neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas regulatory submission based positive results national cancer institute cancer therapy evaluation programsponsored sprint phase stratum trial pdufa date set second quarter v review japan initial indication females prevention certain hpvrelated diseases precursors february fda accepted priority review supplemental bla gardasil prevention certain head neck cancers caused vaccinetype hpv females males years age fda set pdufa date june addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed lynparza addition indications review discussed phase development combination keytruda treatment nsclc lenvima orally available tyrosine kinase inhibitor currently approved certain types thyroid cancer hcc combination certain patients rcc codeveloped part strategic collaboration eisai pursuant agreement companies jointly initiate clinical studies evaluating keytrudalenvima combination six types cancer endometrial cancer nsclc hcc hnscc bladder cancer melanoma well basket trial targeting multiple cancer types fda granted breakthrough therapy designation table contents keytruda combination lenvima potential treatment patients advanced andor metastatic rcc potential treatment patients unresectable hcc amenable locoregional treatment mk gefapixant selective nonnarcotic orallyadministered pxreceptor antagonist investigated phase trials treatment refractory chronic cough phase trial treatment women endometriosisrelated pain mk vericiguat sgc stimulator potential treatment patients worsening chronic heart failure developed part worldwide strategic collaboration merck bayer vericiguat studied patients suffering chronic heart failure reduced ejection fraction phase clinical trial chronic heart failure preserved ejection fraction phase clinical trial november merck announced phase victoria study evaluating efficacy safety vericiguat met primary efficacy endpoint vericiguat reduced risk composite endpoint heart failure hospitalization cardiovascular death patients worsening chronic heart failure reduced ejection fraction compared placebo given combination available heart failure therapies results victoria study presented upcoming medical meeting v investigational polyvalent conjugate vaccine prevention pneumococcal disease june merck initiated first phase study adult population prevention invasive pneumococcal disease currently six phase adult studies ongoing including studies healthy adults years age older adults risk factors pneumococcal disease infected hiv recipients allogeneic hematopoietic stem cell transplant october merck began first phase study pediatric population currently eight studies ongoing including studies healthy infants children afflicted sickle cell disease v received breakthrough therapy designation fda prevention invasive pneumococcal disease caused vaccine serotypes pediatric patients weeks years age adults chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect cancer additional claims line extensions formulations inline products shown table contents phase phase phase entry date review cancer cancer new molecular entitiesvaccines mk keytruda mk keytruda pediatric neurofibromatosis type advanced solid tumors biliary tract september mk selumetinib us mk breast october hpv vaccine renal cell carcinoma cervical october eu v human papillomavirus valent vaccine mk colorectal november recombinant jpn solid tumors cutaneous squamous cell carcinoma certain supplemental filings mk lynparza august eu cancer advanced solid tumors endometrial august eu mk keytruda mk vicriviroc esophageal december eu firstline metastatic nonsmallcell lung colorectal gastric may eu cancer keynote eu mk lenvima hepatocellular may eu firstline metastatic gastric cancer biliary tract mesothelioma may keynote jpn v nasopharyngeal april recurrent locally advanced metastatic melanoma ovarian december esophageal cancer keynote mk prostate may jpn nonsmallcell lung smallcell lung may eu recurrent andor metastatic cutaneous mk mk lynparza squamous cell carcinoma hematological malignancies nonsmallcell lung june keynote us mk mk lenvima alternative dosing regimen hematological malignancies bladder may qw us nonsmallcell lung endometrial june eu mk lynparza mk head neck squamous cell carcinoma firstline gbrcam pancreatic cancer nonsmallcell lung february polo eu mk melanoma march firstline maintenance newly diagnosed nonsmallcell lung nonsmallcell lung march advanced ovarian cancer paola cytomegalovirus cough us eu v mk gefapixant march metastatic prostate cancer profound hiv infection heart failure us eu mk islatravir mk vericiguat september footnotes overgrowth syndrome hiv infection developed collaboration mk mka islatravirdoravirine february developed combination pediatric neurofibromatosis type pneumoconjugate vaccine keytruda mk selumetinib eu v june company received crl february respiratory syncytial virus merck reviewing letter mk discuss next steps fda schizophrenia mk employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups restructuring activities early merck approved new global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs include actions associated planned spinoff newco company continues evaluate global footprint overall operating model subsequently identified additional actions restructuring program could identify actions time actions currently contemplated restructuring program expected substantially completed end actions previous global restructuring programs substantially completed environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome table contents matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial condition results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states percentage total company sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec address website wwwsecgov addition company provide without charge copy annual report including financial statements schedules upon written request shareholder office secretary merck co inc galloping hill road k kenilworth nj usa companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomaboutleadership information available print shareholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company dependent patent rights patent rights invalidated circumvented business could materially adversely affected patent protection considered aggregate material importance companys marketing human health animal health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing table contents sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company defends patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned licensed company company normally responds defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation us certain foreign markets relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company launched commercially successful products replace lost sales addition products measured fair value capitalized connection acquisitions experience difficulties market negatively affect product cash flows company may recognize material noncash impairment charges respect value products chart listing patent protection certain companys marketed products us patent protection candidates phase clinical development set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect companys business cash flow results operations financial condition prospects example patents provided us eu market exclusivity certain forms noxafil expired july december respectively company anticipates significant decline us eu noxafil sales also patent provided us market exclusivity nuvaring expired april generic competition began december company anticipates rapid substantial decline us nuvaring sales result generic competition addition patents provide market exclusivity januvia janumet us expire july although sixmonth pediatric exclusivity may extend date patent provides market exclusivity januvia eu expires july although pediatric exclusivity may extend date september finally spc provides market exclusivity janumet eu expires april company anticipates sales januvia janumet markets decline substantially patent expiries table contents key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys ability generate profits operating cash flow depends largely upon continued profitability companys key products keytruda gardasilgardasil januvia janumet bridion particular companys oncology portfolio led keytruda represented majority companys revenue earnings growth result companys dependence key products event adversely affects products markets products could significant adverse impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop collaborations joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial condition prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following table contents findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications anticipated labeling uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions certain collaborations failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial condition prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu japan china united states fda administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases reduction cost drugs fda foreign regulatory authorities including japan china substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling products jurisdiction company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval may decrease demand companys products including following results postapproval phase trials studies rereview products already marketed recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy quality labeling changes scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse table contents labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pmda chinas nmpa increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities addition dissemination promotional materials evolving digital channels serves increase visibility scrutiny marketplace company faces intense competition lower cost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourage use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial condition prospects company faces intense competition competitors products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use better insurance coverage reimbursement levels effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial condition prospects addition products measured fair value capitalized connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products company faces continued pricing pressure respect products company faces continued pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca iii state activities aimed increasing price transparency including new laws noted item competition health care environment health table contents care environment government regulations changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition united states larger customers received higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company annually posts website pricing transparency report united states report provides companys average annual list price net price increases across companys us portfolio dating back companys gross us sales reduced approximately result rebates discounts returns outside united states numerous major markets including eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occur furthermore government order repricing specific products determines use product exceed certain thresholds defined applicable repricing rules example pursuant repricing rule japanese government reduced price keytruda effective february additionally keytruda subject another significant price reduction april provision japanese pricing rules company expects pricing pressures continue future health care industry united states continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered executive branch congress state legislatures united states enacted major health care reform legislation form aca various insurance market reforms advanced state federal insurance exchanges launched aca increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program aca also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole increased extended biosimilar products companys revenue reduced approximately million due requirement also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee company recorded million costs annual fee centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective addition discussed competition health care environment administration recently proposed draft rule would allow importation certain lowercost prescription drugs canada rule finalized proposed states certain nonfederal governmental entities would able submit importation program proposals fda review authorization twoyear programs opportunity extend two years public comment period proposed rule expire march following comment period fda review finalize proposal states table contents parties submit plans comply federal rule proposed rule adopted likely time states parties actually implement importation plans also october administration issued advance notice proposed rulemaking implement international pricing index ipi model united states products covered medicare part b proposal would reduce medicare part b payments drugs based market basket international prices allow private sector vendors negotiate prices drugs take title drugs compete physician hospital business change physician reimbursement medicare part b current model eliminate buy bill system instead pay physicians based flat fee approximates revenue currently receive drugs public comments ipi proposal accepted late unclear agency may issue proposed rule ipi model adoption one proposed rules could material adverse effect companys business results operations financial condition company predict likelihood additional future changes health care industry general pharmaceutical industry particular impact may companys business cash flow results operations financial condition prospects company increasingly dependent sophisticated software applications computing infrastructure company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks company increasingly dependent sophisticated software applications complex information technology systems computing infrastructure collectively systems conduct critical operations certain systems managed hosted provided used third parties assist conducting companys business disruption degradation manipulation systems intentional accidental means companys employees third parties authorized access unauthorized third parties could adversely affect key business processes cyberattacks companys systems thirdparty providers systems cloudbased systems could result exposure confidential information modification critical data andor failure critical operations misuse systems could result disclosure sensitive personal information theft trade secrets intellectual property confidential business information company continues leverage new innovative technologies across enterprise improve efficacy efficiency business processes use create new risks company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations resulting losses company insurance coverage insuring losses resulting cyberattacks received proceeds connection cyber attack however disputes certain insurers availability insurance coverage claims related cyberattack company implemented variety measures enhance modernize systems guard similar attacks future also pursuing enterprisewide effort enhance company 's resiliency future cyberattacks including incidents similar attack objective efforts protect future cyberattacks also improve speed companys recovery attacks enable continued business operations greatest extent possible recovery period although aggregate impact cyberattacks network disruptions including cyberattack companys operations financial condition material date company continues target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems efforts thirdparty providers protect systems successful preventing disruptions companys operations including manufacturing research sales operations disruptions past could future result loss revenue loss critical sensitive information companys companys thirdparty providers databases systems past could future also result financial legal business reputational harm company substantial remediation costs table contents company subject variety us international laws regulations company currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business cash flow results operations financial condition prospects company laws regulations include additional healthcare reform initiatives united states countries including additional mandatory discounts fees ii us foreign corrupt practices act antibribery corruption laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement access marketing within across jurisdictions iv changes intellectual property laws v changes accounting standards vi new increasing data privacy regulations enforcement particularly eu united states vii legislative mandates preferences local manufacturing pharmaceutical vaccine products viii emerging new global regulatory requirements reporting payments value transfers healthcare professionals ix environmental regulations x potential impact importation restrictions embargoes trade sanctions legislative andor regulatory changes uncertainty global economic conditions together costreduction measures taken certain governments could negatively affect companys operating results uncertainty global economic geopolitical conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial condition prospects global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments thirdparties lower health care costs company anticipates actions additional actions future continue negatively affect revenue performance credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements including imposition trade sanctions similar restrictions united states governments foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease table contents united kingdom uk held referendum voters approved exit eu commonly referred brexit result referendum subsequent negotiations uk left eu january transitional period apply january december period eu treat uk eu member state uk continue participate eu customs union allowing freedom movement people goods transitional period eu uk continue negotiate trade agreement formalize terms uks future relationship eu company taken actions made certain contingency plans scenarios uk eu reach mutually satisfactory understanding future trade agreement possible time predict whether understanding end understanding reached whether terms vary ways result greater restrictions imports exports uk eu countries increased regulatory complexities andor cross border labor issues could materially adversely impact companys business operations uk failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel costs materially increase past company experienced difficulties delays manufacturing certain products including vaccines merck past experienced difficulties manufacturing certain products including vaccines addition network cyberattack experienced company june led disruption companys operations including manufacturing operations company may future experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply addition company could experience difficulties delays manufacturing products caused natural disasters hurricanes example companys lone manufacturing plant puerto rico negatively affected hurricane maria manufacturing difficulties result product shortages leading lost sales reputational harm company company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business outside united states increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys currently marketed products absence trade impediments adverse pricing controls noted health care environment government regulation pricing pressure china increased chinese government taking steps reduce costs including implementing healthcare reform led acceleration generic table contents substitution available pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution governments vbp program government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered first two rounds vbp average price reduction expansion vbp program remains seen addition company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue also december new coronavirus known covid proved highly contagious emerged wuhan china outbreak virus caused material disruptions chinese economy including health care system negative effect companys first quarter results time expected material since future course duration covid outbreak unknown company currently unable determine whether outbreak negative effect companys results outbreak covid currently also limited effect companys supply chain drugs raw materials china outbreak also negatively affected certain companys clinical trials reasons sales within emerging markets carry significant risks however failure maintain companys presence emerging markets could material adverse effect companys business cash flow results operations financial condition prospects company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter business development transactions borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates inflation could negatively affect companys business cash flow results operations financial condition prospects order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful certain companys interest rate derivatives investments based london interbank offered rate libor portion mercks indebtedness bears interest variable interest rates primarily based libor libor subject recent national international regulatory guidance proposals reform may cause libor cease exist entirely company expects reasonable alternatives libor implemented prior target date company predict consequences timing developments could include increase interest expense may also require amendment contracts reference libor company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may negatively affected changes tax laws new tax laws affecting example tax rates andor revised tax law interpretations domestic foreign jurisdictions table contents pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies thirdparty service providers key aspects business including development manufacture commercialization products support systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business negative events animal health industry could material adverse effect future results operations financial condition future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals african swine fever could lead widespread death precautionary destruction well reduced consumption demand animals could adversely affect companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition successful development testing manufacturing commercialization biologics vaccines particularly human animal health vaccines long complex expensive uncertain process unique risks uncertainties related biologics vaccines including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics vaccines subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval generally required release manufactured commercial lot manufacturing biologics vaccines especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic vaccine must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made table contents manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics vaccines frequently costly manufacture production ingredients derived living animal plant material biologics vaccines made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead variability manufacturing process could lead allegations harm including infections allergic reactions allegations would reviewed standard investigation process could lead closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost insurance increased significantly company subject substantial number product liability claims see item financial statements supplementary data note contingencies environmental liabilities information companys current product liability litigation respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise social media platforms present risks challenges inappropriate andor unauthorized use certain social media channels could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company products social networking platforms could damage companys reputation brand image goodwill disclosure nonpublic companysensitive information companys workforce others external media channels could lead information loss although internal company social media policy guides employees appropriate personal professional use social media company processes place may completely secure protect information identifying new points entry social media continues expand also presents new challenges risks related proposed spinoff newco proposed spinoff newco may completed terms timeline currently contemplated may achieve expected results february company announced intention spinoff products womens health trusted legacy brands biosimilars businesses new yettobenamed independent publicly traded company newco distribution newcos publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes transaction expected completed first half completion spinoff subject number factors conditions assurances company able complete spinoff terms timeline announced unanticipated developments could delay prevent otherwise adversely affect proposed spinoff including limited disruptions general financial market conditions potential problems delays obtaining various regulatory tax approvals clearances addition consummation proposed spinoff require final approval companys board directors table contents costs complete proposed spinoff significant addition company may unable achieve strategic financial benefits expects achieve spinoff newco company incur significant expenses connection spinoff addition company may able achieve full strategic financial benefits expected result spinoff anticipated benefits spinoff based number assumptions may prove incorrect following spinoff price shares companys common stock may fluctuate significantly company predict effect spinoff trading price shares common stock market value shares common stock may less equal greater market value shares common stock prior spinoff addition price mercks common stock may volatile around time spinoff could significant income tax liability spinoff certain related transactions determined taxable us federal income tax purposes company expects prior completion spinoff receive opinion us tax counsel concludes among things spinoff outstanding newco shares merck shareholders certain related transactions qualify taxfree merck shareholders sections us internal revenue code except extent cash received lieu fractional shares newco common stock opinion binding internal revenue service irs accordingly company believes risk low irs may reach conclusions respect spinoff different conclusions reached opinion opinion rely certain facts assumptions representations undertakings merck newco regarding past future conduct companies respective businesses matters incomplete incorrect satisfied could alter conclusions party giving opinion proposed spinoff ultimately determined taxable company believes unlikely spinoff could treated taxable dividend mercks shareholders us federal income tax purposes mercks shareholders could incur significant us federal income tax liabilities addition merck would recognize taxable gain extent fair market value newco common stock exceeds mercks tax basis stock date spinoff cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance table contents difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products cyberattacks companys thirdparty providers information technology systems could disrupt companys operations lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates proposed spinoff might delayed costs complete spinoff might significant expected list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located kenilworth new jersey company also maintains operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal us research facilities located rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts south san francisco california elkhorn nebraska animal health principal research facilities outside united states located united kingdom switzerland table contents china mercks manufacturing operations headquartered whitehouse station new jersey company also production facilities human health products nine locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia capital expenditures billion billion billion united states amounted billion billion billion abroad expenditures amounted billion billion million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained company believes plants manufacture products suitable intended purposes capacities projected capacities including previouslydisclosed capital expansion projects adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer persons name age offices business experience kenneth c frazier chairman president chief executive officer since december sanat chattopadhyay executive vice president president merck manufacturing division since march senior vice president operations merck manufacturing division november march frank clyburn executive vice president chief commercial officer since january president global oncology business unit october december robert davis executive vice president global services chief financial officer since april executive vice president chief financial officer april april richard r deluca jr executive vice president president merck animal health since september michael w fleming senior vice president chief ethics compliance officer since march senior vice president international legal compliance january march vice president international legal compliance july january julie l gerberding executive vice president chief patient officer strategic communications global public policy population health since july executive vice president strategic communications global public policy population health january july rita karachun senior vice president finance global controller since march steven c mizell executive vice president chief human resources officer since october executive vice president chief human resources officer december october executive vice president human resources monsanto company august december michael nally executive vice president chief marketing officer since january president global vaccines global human health september january managing director united kingdom ireland global human health january september roger perlmutter md phd executive vice president president merck research laboratories since april executive vice president general counsel corporate secretary since january executive vice president general counsel april january partner covington burling llp jennifer zachary january march table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk january approximately shareholders record companys common stock issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total shares purchased period made part plan approved board directors october purchase billion merck shares treasury table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major us europeanbased pharmaceutical companies abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculated market cap weighted basis performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales cost sales selling general administrative research development restructuring costs income expense net income taxes taxes income net income less net loss income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends declared per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include charge acquisition peloton therapeutics inc amounts include charge related formation collaboration eisai co ltd amounts include provisional net tax charge related enactment us tax legislation charge related formation collaboration astrazeneca plc amounts include charge related settlement worldwide patent litigation related keytruda amounts include net charge related settlement vioxx shareholder class action litigation foreign exchange losses related venezuela gains dispositions businesses assets favorable benefit certain tax items table contents item managements discussion analysis financial condition results operations following section generally discusses results yeartoyear comparisons discussion results yeartoyear comparisons included found managements discussion analysis financial condition results operations part ii item companys annual report fiscal year ended december filed february description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients company recently sold certain businesses healthcare services segment process divesting remaining businesses company continues look investment opportunities area health care approach investments shifted toward venture capital investments third parties opposed whollyowned businesses alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded planned spinoff womens health legacy brands biosimilars new company february merck announced intention spinoff products womens health trusted legacy brands biosimilars businesses new yettobenamed independent publicly traded company newco distribution newcos publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes legacy brands included transaction consist dermatology pain respiratory select cardiovascular products including zetia vytorin well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned newco development capabilities initially focused latestage development lifecycle management expected time develop research capabilities selected therapeutic areas spinoff expected completed first half subject market certain conditions overview mercks performance demonstrates execution commercial research operations driven focus key growth drivers innovative pipeline investment reinforcing companys scienceled strategy merck enhanced portfolio pipeline external innovation increased investment new capital projects focused primarily expanding manufacturing capacity across mercks key businesses returned capital shareholders table contents worldwide sales billion increase compared including unfavorable effect foreign exchange sales increase driven primarily mercks growth pillars oncology human health vaccines certain hospital acute care products animal health growth areas partially offset ongoing effects generic competition particularly diversified brands cardiovascular franchises well competitive pressure particularly diabetes virology franchises merck continued prioritize business development aimed enhancing portfolio strengthening pipeline executing several business development transactions expand oncology presence merck completed acquisitions peloton therapeutics inc peloton clinicalstage biopharmaceutical company focused development novel small molecule therapeutic candidates treatment cancer diseases immune design latestage immunotherapy company employing nextgeneration vivo approaches enable bodys immune system fight disease merck also announced agreement acquire arqule inc arqule biopharmaceutical company focused kinase inhibitor discovery development treatment cancer diseases acquisition closed january augment mercks animal health business company acquired antelliq group antelliq leader digital animal identification traceability monitoring solutions company received numerous regulatory approvals progressed many important pipeline candidates clinical development within oncology keytruda received multiple additional approvals united states european union eu china japan monotherapy therapeutic areas nonsmallcell lung cancer nsclc smallcell lung cancer sclc esophageal cancer combination axitinib treatment renal cell carcinoma rcc combination chemotherapy head neck squamous cell carcinoma hnscc combination lenvima endometrial carcinoma lynparza developed collaboration astrazeneca plc astrazeneca received us food drug administration fda approval treatment appropriate patients germline brcamutated gbrcam pancreatic cancer european commission ec approval use certain patients advanced ovarian cancer advanced metastatic breast cancer addition oncology company received regulatory approvals hospital acute care vaccines therapeutic areas fda approved recarbrio imipenem cilastatin relebactam injection new combination antibacterial treatment certain patients complicated urinary tract infections caused certain gramnegative microorganisms recarbrio approved ec february fda ec also approved expanded indications zerbaxa treatment patients hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia habpvabp caused certain susceptible gramnegative microorganisms additionally ervebo ebola zaire vaccine live vaccine prevention disease caused zaire ebolavirus adults approved united states received conditional approval eu addition recent regulatory approvals discussed company advanced latestage pipeline particularly oncology several regulatory submissions keytruda lynparza lenvima united states internationally companys phase oncology programs include keytruda therapeutic areas biliary tract breast cervical colorectal cutaneous squamous cell endometrial esophageal gastric hepatocellular mesothelioma nasopharyngeal ovarian prostate smallcell lung cancers lynparza combination keytruda nonsmall cell lung cancer lenvima combination keytruda bladder endometrial head neck melanoma nonsmallcell lung cancers additionally company candidates phase clinical development several therapeutic areas including v investigational polyvalent conjugate vaccine prevention pneumococcal disease received breakthrough therapy designation fda prevention invasive pneumococcal disease caused vaccine serotypes pediatric patients weeks years age adults mk gefapixant selective nonnarcotic orallyadministered pxreceptor antagonist developed treatment refractory chronic cough mka islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti combination doravirine treatment hiv infection mk vericiguat investigational treatment heart failure developed collaboration see research development company allocating resources effectively support commercial opportunities near term making necessary investments support longterm growth research development expenses reflect higher clinical development spending increased investment discovery research early drug development table contents november mercks board directors approved increase companys quarterly dividend raising per share per share companys outstanding common stock company returned billion shareholders dividends share repurchases earnings per common share assuming dilution attributable common shareholders eps compared eps years reflects impact acquisition divestiturerelated costs well restructuring costs certain items certain items include charge related acquisition peloton include charge related formation collaboration eisai co ltd eisai nongaap eps excludes items see nongaap income nongaap eps pricing global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments thirdparties lower health care costs company anticipates actions additional actions future continue negatively affect revenue performance operating results sales change change excluding excluding millions change exchange change exchange united states international total us plus international may equal total due rounding worldwide sales grew driven primarily higher sales oncology franchise reflecting strong growth keytruda well increased alliance revenue related lynparza lenvima also contributing revenue growth higher sales vaccines including gardasilgardasil varivax proquad mmr ii well increased sales certain hospital acute care products including bridion higher sales animal health products also drove revenue growth sales growth partially offset effects generic competition cardiovascular products zetia vytorin hospital acute care products invanz cubicin noxafil oncology product emend products within diversified brands franchise well biosimilar competition immunology product remicade diversified brands franchise includes certain products approaching expiration marketing exclusivity longer protected patents developed markets lower sales diabetes products januvia janumet hiv products isentressisentress hd also partially offset revenue growth sales united states grew driven primarily higher sales keytruda combined sales proquad mmr ii varivax bridion well higher alliance revenue lenvima lynparza revenue growth partially offset lower sales januvia janumet invanz emend isentressisentress hd cubicin noxafil international sales grew performance international markets led china total sales billion representing growth compared including unfavorable effect foreign exchange increase international sales primarily reflects growth keytruda gardasilgardasil combined sales proquad mmr ii varivax well higher alliance revenue lynparza lenvima sales growth partially offset lower sales zetia vytorin zepatier remicade products within diversified brands franchise international sales represented total sales see note consolidated financial statements details sales companys products discussion performance select products franchises follows table contents pharmaceutical segment oncology change change excluding excluding millions change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima na na emend calculation meaningful alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note consolidated financial statements keytruda antipd therapy approved treatment multiple malignancies including cervical cancer classical hodgkin lymphoma chl esophageal cancer gastric gastroesophageal junction adenocarcinoma hnscc hepatocellular carcinoma hcc nsclc sclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient cancer primary mediastinal large bcell lymphoma pmbcl rcc urothelial carcinoma keytruda clinical development program includes studies across broad range cancer types see research development january fda approved keytruda monotherapy treatment certain patients bacillus calmetteguerin bcgunresponsive highrisk nonmuscle invasive bladder cancer nmibc based results keynote trial july fda approved keytruda monotherapy treatment certain patients recurrent locally advanced metastatic squamous cell carcinoma esophagus whose tumors express pdl combined positive score cps determined fdaapproved test based results keynote keynote trials june fda approved keytruda monotherapy combination chemotherapy firstline treatment patients metastatic unresectable recurrent hnscc based results pivotal phase keynote trial keytruda initially approved hnscc fdas accelerated approval process based data phase b keynote trial accordance accelerated approval process continued approval contingent upon verification description clinical benefit demonstrated keynote resulted fda converting accelerated approval full regular approval keytruda approved indications ec november japans ministry health labour welfare mhlw december also june fda approved keytruda monotherapy treatment certain patients metastatic sclc based pooled data keynote cohort g keynote cohort c clinical trials april fda approved keytruda combination inlyta axitinib tyrosine kinase inhibitor firstline treatment patients advanced rcc common type kidney cancer based findings pivotal phase keynote trial keytruda approved indication ec september japans mhlw december also april fda approved expanded label keytruda monotherapy firstline treatment patients nsclc expressing pd l tumor proportion score tps determined fdaapproved test egfr alk genomic tumor aberrations stage iii disease patients candidates surgical resection definitive chemoradiation metastatic disease approval based results phase keynote trial september fda approved combination keytruda plus lenvima treatment certain patients advanced endometrial carcinoma msih mismatch repair deficient table contents march ec approved keytruda combination carboplatin either paclitaxel nabpaclitaxel firstline treatment adults metastatic squamous nsclc based data phase keynote trial keytruda approved indication fda october april ec approved new extended dosing schedule mg every six weeks qw delivered intravenous infusion minutes approved monotherapy indications eu qw dose available addition formerly approved dose keytruda mg every three weeks qw infused minutes additionally keytruda received following approvals chinas national medical products administration nmpa combination pemetrexed platinum chemotherapy firstline treatment patients metastatic nonsquamous nsclc egfr alk genomic tumor aberrations based data pivotal phase keynote trial monotherapy firstline treatment patients locally advanced metastatic nsclc whose tumors express pdl determined nmpaapproved test egfr alk genomic tumor aberrations based results phase keynote trial combination carboplatin paclitaxel firstline treatment patients metastatic squamous nsclc based findings pivotal phase keynote trial global sales keytruda grew driven higher demand company continues launch keytruda multiple new indications globally sales united states continue build across multiple approved indications particular treatment nsclc monotherapy combination chemotherapy nonsquamous squamous metastatic nsclc along uptake recently launched rcc adjuvant melanoma indications indications contributing us sales growth include hnscc urothelial carcinoma melanoma msih cancer keytruda sales growth international markets driven primarily performance europe japan china reflecting increased use treatment nsclc well recently approved indications described company party certain thirdparty license agreements pursuant company pays royalties sales keytruda terms significant agreements merck pays royalty worldwide sales keytruda one third party royalty decline terminate thereafter company pays additional royalty worldwide sales keytruda another third party termination date varies country royalty expire united states major european markets royalties included cost sales pursuant repricing rule japanese government reduced price keytruda effective february additionally keytruda subject another significant price reduction april provision japanese pricing rules lynparza oral poly adpribose polymerase parp inhibitor developed part collaboration astrazeneca entered july see note consolidated financial statements approved treatment certain types advanced ovarian breast pancreatic cancers increase alliance revenue related lynparza driven primarily expanded use united states eu japan china reflecting part ongoing launch new indications lynparza received approval treatment certain types advanced ovarian cancer united states december eu japan june china december based results phase solo trial also april ec approved lynparza treatment certain adult patients advanced breast cancer based results phase olympiad trial additionally december fda approved lynparza maintenance treatment certain adult patients advanced pancreatic cancer based results phase polo trial lenvima oral receptor tyrosine kinase inhibitor developed part collaboration eisai entered march see note consolidated financial statements approved treatment certain types thyroid cancer hcc combination evorolimus certain patients rcc additionally september fda approved combination keytruda plus lenvima treatment certain patients advanced endometrial carcinoma msih mismatch repair deficient marks first us approval combination keytruda plus lenvima increase alliance revenue related lenvima reflects strong performance treatment hcc following recent worldwide launches well full year collaboration activity table contents global sales emend prevention chemotherapyinduced postoperative nausea vomiting declined driven primarily lower demand pricing united states due competition including recent generic competition emend injection following us patent expiry september patent provided us market exclusivity emend expired patent provided market exclusivity major european markets expired may additionally emend injection lose market exclusivity major european markets august company anticipates sales emend injection markets decline significantly thereafter vaccines change change excluding excluding millions change exchange change exchange gardasilgardasil proquad mmr ii varivax rotateq worldwide sales gardasilgardasil vaccines help prevent certain cancers diseases caused certain types hpv grew driven primarily higher demand asia pacific region particularly china higher demand certain european markets reflecting increased vaccination rates boys girls growth partially offset lower sales united states us sales decline driven borrowing gardasil doses us centers disease control prevention cdc pediatric vaccine stockpile offset part higher demand pricing company borrowed doses gardasil cdc pediatric vaccine stockpile borrowing reduced sales approximately million company recognized corresponding liability company replenished doses borrowed cdc pediatric vaccine stockpile resulting recognition sales million reversal liability related borrowing decision japans mhlw suspend active recommendation hpv vaccination still review company party certain thirdparty license agreements pursuant company pays royalties sales gardasilgardasil terms significant agreements merck pays royalty worldwide sales gardasilgardasil one third party agreement expires december additional royalty sales gardasilgardasil united states another third party agreement expires december royalties included cost sales global sales proquad pediatric combination vaccine help protect measles mumps rubella varicella grew driven primarily higher volumes pricing united states well volume growth eu largely reflecting competitor supply issue worldwide sales mmr ii vaccine help protect measles mumps rubella grew driven primarily higher sales united sates reflecting increased demand due measles outbreaks well higher pricing company anticipates us sales mmr ii decline driven lower expected demand related fewer measles outbreaks global sales varivax vaccine help prevent chickenpox varicella grew driven primarily government tenders latin america well higher pricing volume growth united states varivax sales expected decline due part timing government tenders competition select latin american markets global sales rotateq vaccine help protect rotavirus gastroenteritis infants children grew driven primarily continued uptake launch china higher volumes united states partially offset lower volumes latin america table contents december fda approved ervebo prevention disease caused zaire ebolavirus individuals years age older previously announced merck working initiate manufacturing licensed doses expects doses start becoming available approximately third quarter merck working closely us government world health organization unicef gavi vaccine alliance plan eventual licensed doses support future public health preparedness response efforts zaire ebolavirus disease merck seeking profit sales vaccine rather ensure vaccine sustainable recovering manufacturing operational costs associated program ervebo also granted conditional marking authorization ec additionally merck made submissions african country national regulatory authorities collaboration african vaccine regulatory forum allow vaccine registered african countries considered atrisk ebola outbreaks february merck confirmed four african countries approved ervebo approvals additional countries africa anticipated near future hospital acute care change change excluding excluding millions change exchange change exchange bridion noxafil invanz cubicin global sales bridion reversal two types neuromuscular blocking agents used surgery grew driven higher demand globally particularly united states worldwide sales noxafil prevention invasive fungal infections declined driven primarily generic competition united states patent provided us market exclusivity certain forms noxafil representing majority us noxafil sales expired july accordingly company experiencing decline us noxafil sales result generic competition expects decline continue additionally patent noxafil expired number major european markets december result company anticipates sales noxafil markets decline significantly future periods global sales invanz treatment certain infections declined driven generic competition united states patent provided us market exclusivity invanz expired november generic competition began second half company subsequently experienced significant decline invanz sales united states result generic competition since lost us invanz sales global sales cubicin iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms declined resulting primarily ongoing generic competition united states following expiration us composition patent cubicin fda ec approved expanded indications zerbaxa treatment habpvabp caused certain susceptible gramnegative microorganisms based results pivotal phase aspectnp trial zerbaxa previously approved united states eu treatment adults certain complicated urinary tract intraabdominal infections july fda approved recarbrio injection new combination antibacterial treatment adults limited alternative treatment options complicated urinary tract infections complicated intraabdominal infections caused certain susceptible gramnegative microorganisms recarbrio approved ec february merck anticipates making recarbrio available first half january fda approved dificid fidaxomicin oral suspension dificid tablets treatment clostridioides formerly clostridium difficileassociated diarrhea children aged six months older table contents immunology change change excluding excluding millions change exchange change exchange simponi remicade sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey declined driven unfavorable effect foreign exchange lower pricing europe sales simponi unfavorably affected launch biosimilars competing product company expects competition continue unfavorably affect sales simponi sales remicade treatment inflammatory diseases marketed company europe russia turkey declined driven ongoing biosimilar competition companys marketing territories company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition expects declines continue virology change change excluding excluding millions change exchange change exchange isentressisentress hd worldwide sales isentressisentress hd hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection declined primarily reflecting lower demand united states eu due competitive pressure september fda approved supplemental new drug applications nda pifeltro doravirine combination antiretroviral agents delstrigo doravirinelamivudinetenofovir disoproxil fumarate complete regimen expand indications include adult patients hiv infection virologically suppressed stable antiretroviral regimen cardiovascular change change excluding excluding millions change exchange change exchange zetiavytorin atozet rosuzet adempas combined global sales zetia marketed countries outside united states ezetrol vytorin marketed outside united states inegy medicines lowering ldl cholesterol declined driven primarily lower sales eu eu patents ezetrol inegy expired april april respectively accordingly company experiencing sales declines markets result generic competition expects declines continue sales decline also attributable loss exclusivity australia merck lost market exclusivity united states zetia vytorin subsequently lost nearly us sales products result generic competition sales atozet marketed outside united states medicine lowering ldl cholesterol grew primarily driven higher demand eu korea sales rosuzet marketed outside united states medicine lowering ldl cholesterol doubled primarily driven launch japan well higher demand korea table contents adempas cardiovascular drug treatment pulmonary arterial hypertension part worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including adempas see note consolidated financial statements increase alliance revenue driven higher profits bayer higher sales adempas mercks marketing territories diabetes change change excluding excluding millions change exchange change exchange januviajanumet worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes declined result continued pricing pressure united states partially offset higher demand international markets company expects us pricing pressure continue patents provide market exclusivity januvia janumet united states expire july although sixmonth pediatric exclusivity may extend date patent provides market exclusivity januvia eu expires july although pediatric exclusivity may extend date september supplementary patent certificate provides market exclusivity janumet eu expires april company anticipates sales januvia janumet markets decline substantially patent expiries womens health change change excluding excluding millions change exchange change exchange nuvaring implanonnexplanon worldwide sales nuvaring vaginal contraceptive product declined driven primarily lower demand eu due generic competition largely offset higher sales united states reflecting higher pricing partially offset lower demand patent provided us market exclusivity nuvaring expired april generic competition began december company anticipates rapid substantial decline us nuvaring sales result generic competition worldwide sales implanonnexplanon singlerod subdermal contraceptive implant grew primarily driven higher demand pricing united states biosimilars change change excluding excluding millions change exchange change exchange biosimilars calculation meaningful biosimilar products marketed company pursuant agreement samsung bioepis co ltd samsung develop commercialize multiple prespecified biosimilar candidates currently company markets renflexis infliximababda tumor necrosis factor tnf antagonist biosimilar remicade infliximab treatment certain inflammatory diseases ontruzant trastuzumabdttb human epidermal growth factor receptor neu receptor antagonist biosimilar herceptin trastuzumab treatment herpositive breast cancer overexpressing gastric cancer brenzys etanercept biosimilar tnf antagonist biosimilar enbrel treatment certain inflammatory diseases mercks commercialization territories agreement vary product sale growth biosimilars driven continued uptake renflexis united states since launch continued uptake ontruzant eu since launch launch brenzys brazil table contents animal health segment change change excluding excluding millions change exchange change exchange livestock companion animal sales livestock products grew predominantly due products obtained april acquisition antelliq leader digital animal identification traceability monitoring solutions see note consolidated financial statements growth sales livestock products also driven higher demand aqua swine products sales companion animal products grew driven primarily higher demand bravecto line products parasitic control costs expenses millions change change cost sales selling general administrative research development restructuring costs income expense net greater cost sales cost sales billion compared billion cost sales includes amortization intangible assets recorded connection business acquisitions totaled billion compared billion cost sales also includes amortization amounts capitalized connection collaborations million compared million see note consolidated financial statements additionally costs include intangible asset impairment charges million related marketed products recorded connection business acquisitions see note consolidated financial statements company may recognize additional noncash impairment charges future related intangible assets measured fair value capitalized connection business acquisitions charges could material costs include million charge related termination collaboration agreement samsung insulin glargine see note consolidated financial statements also included cost sales expenses associated restructuring activities amounted million compared million primarily reflecting accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared gross margin improvement reflects charge recorded connection termination collaboration agreement samsung noted favorable product mix lower amortization intangible assets noted improvements gross margin partially offset unfavorable manufacturing variances inventory writeoffs pricing pressure higher restructuring costs selling general administrative selling general administrative sga expenses billion increase compared driven primarily higher administrative costs acquisition divestiturerelated costs largely related acquisition antelliq promotional expenses primarily support strategic brands restructuring costs partially offset favorable effect foreign exchange lower selling costs sga expenses include restructuring costs million related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed sga expenses include acquisition divestiturerelated costs million compared table contents million consisting integration transaction certain costs related business acquisitions divestitures research development research development rd expenses billion increase compared increase driven primarily million charge acquisition peloton see note consolidated financial statements well higher expenses related clinical development increased investment discovery research early drug development increase rd expenses partially offset billion charge related formation oncology collaboration eisai see note consolidated financial statements million charge related acquisition viralytics limited viralytics see note consolidated financial statements favorable effect foreign exchange rd expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities billion compared billion also included rd expenses animal health research costs licensing costs costs incurred divisions support rd activities including depreciation production general administrative aggregate billion billion rd expenses also include inprocess research development iprd impairment charges million million respectively see note consolidated financial statements company may recognize additional noncash impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business acquisitions charges could material addition rd expenses include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection business acquisitions company recorded net reduction expenses million million respectively related changes estimates restructuring costs early merck approved new global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs include actions associated planned spinoff newco company continues evaluate global footprint overall operating model subsequently identified additional actions restructuring program could identify actions time actions currently contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion company expects record charges approximately million related restructuring program company anticipates actions restructuring program result annual net cost savings approximately million end actions previous global restructuring programs substantially completed restructuring costs primarily representing separation related costs associated restructuring activities million million separation costs incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated also included restructuring costs asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included cost sales selling general administrative research development company recorded aggregate pretax costs million million related restructuring program activities see note consolidated financial statements table contents income expense net details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits animal health segment profits nonreportable segment profits income taxes pharmaceutical segment profits comprised segment sales less standard costs well sga expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well sga rd expenses directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred mrl general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits costs related restructuring activities acquisition divestiturerelated costs including amortization purchase accounting adjustments intangible asset impairment charges changes estimated fair value measurement liabilities contingent consideration additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales result changes companys internal reporting structure certain costs previously included pharmaceutical segment included part nonsegment expenses within mrl prior period pharmaceutical segment profits recast reflect changes comparable basis pharmaceutical segment profits grew compared driven primarily higher sales well lower selling costs animal health segment profits declined driven primarily unfavorable product mix higher investments selling product development unfavorable effect foreign exchange partially offset higher sales taxes income effective income tax rates reflect impacts acquisition divestiturerelated costs restructuring costs beneficial impact foreign earnings including product mix effective income tax rate also reflects favorable impact million net tax benefit related settlement certain federal income tax matters see note consolidated financial statements reversal tax reserves established connection divestiture mercks consumer care mcc business due lapse statute limitations addition effective income tax rate reflects unfavorable impacts charge acquisition peloton tax benefit recognized charges million related finalization treasury regulations transition tax associated enactment us tax legislation known tax cuts jobs act tcja see note consolidated financial statements effective income tax rate includes measurementperiod adjustments provisional amounts recorded associated enactment tcja including million related transition tax addition effective income tax rate reflects unfavorable impacts charge recorded connection formation collaboration eisai charge related termination collaboration agreement samsung tax benefit recognized table contents net loss income attributable noncontrolling interests net loss income attributable noncontrolling interests million compared million losses driven primarily portion goodwill impairment charges related certain business healthcare services segment attributable noncontrolling interests net income earnings per common share net income attributable merck co inc billion billion eps nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results permits investors understand management assesses performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps management uses measures internally planning forecasting purposes measure performance company along metrics addition senior managements annual compensation derived part using nongaap pretax income since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance generally accepted accounting principles united states gaap table contents reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts income taxes reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs items charge acquisition peloton charge related formation oncology collaboration eisai charge related termination collaboration samsung charge acquisition viralytics charge related formation oncology collaboration astrazeneca nongaap income taxes taxes income reported gaap estimated tax benefit excluded items net tax charge related enactment tcja subsequent finalization related treasury regulations net tax benefit settlement certain federal income tax matters tax benefit reversal tax reserves related divestiture mcc tax benefit related settlement state income tax matter nongaap taxes income nongaap net income less net loss income attributable noncontrolling interests reported gaap acquisition divestiturerelated costs attributable noncontrolling interests nongaap net income attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments amount provisional see note consolidated financial statements acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection business acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration also excluded integration transaction certain costs associated business acquisitions divestitures restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site table contents closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs certain items items adjusted evaluated individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps charge acquisition peloton see note consolidated financial statements tax charges related finalization us treasury regulations related tcja net tax benefit related settlement certain federal income tax matters tax benefit related reversal tax reserves established connection divestiture mcc see note consolidated financial statements excluded nongaap income nongaap eps charge related formation collaboration eisai see note consolidated financial statements charge related termination collaboration agreement samsung insulin glargine see note consolidated financial statements charge acquisition viralytics see note consolidated financial statements measurementperiod adjustments related provisional amounts recorded tcja see note consolidated financial statements excluded nongaap income nongaap eps charge related formation collaboration astrazeneca see note consolidated financial statements well provisional net tax charge related enactment tcja net tax benefit related settlement certain federal income tax matters tax benefit related settlement state income tax matter see note consolidated financial statements research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently several candidates regulatory review united states internationally keytruda antipd therapy approved treatment many cancers clinical development expanded indications approvals result broad clinical development program currently consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including biliary tract cervical colorectal cutaneous squamous cell endometrial gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma mesothelioma nasopharyngeal nonsmallcell lung ovarian pmbcl prostate renal smallcell lung triplenegative breast urothelial many currently phase clinical development trials planned cancers keytruda review eu monotherapy firstline treatment patients stage iii nsclc candidates surgical resection definitive chemoradiation metastatic nsclc whose tumors express pdl tps egfr alk genomic tumor aberrations based results phase keynote trial keytruda review japan monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma based results pivotal phase keynote trial keytruda also review japan monotherapy secondline treatment advanced metastatic esophageal esophagogastric junction carcinoma based results phase keynote trial merck made decision withdraw type ii variation application keytruda indication eu october fda accepted supplemental biologics license application bla seeking use keytruda treatment patients recurrent andor metastatic cutaneous squamous cell carcinoma cscc table contents curable surgery radiation based results keynote trial fda set prescription drug user fee act pdufa date june february merck announced fda issued complete response letter regarding mercks supplemental blas seeking update dosing frequency keytruda include mg dose infused minutes everysixweeks qw option multiple indications submitted applications based pharmacokinetic modeling simulation data presented american society clinical oncology asco annual meeting data supported ec approval mg qw dosing keytruda monotherapy indications march merck reviewing letter discuss next steps fda additionally keytruda received breakthrough therapy designation fda combination neoadjuvant chemotherapy treatment highrisk earlystage triplenegative breast cancer tnbc combination enfortumab vedotin firstline setting treatment patients unresectable locally advanced metastatic urothelial cancer eligible cisplatincontaining chemotherapy fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints september merck announced results pivotal neoadjuvantadjuvant phase keynote trial patients earlystage tnbc trial investigated regimen neoadjuvant keytruda plus chemotherapy followed adjuvant keytruda monotherapy keytruda regimen compared regimen neoadjuvant chemotherapy followed adjuvant placebo chemotherapyplacebo regimen interim findings presented european society medical oncology esmo congress neoadjuvant phase keytruda plus chemotherapy resulted statistically significant increase pathological complete response pcr versus chemotherapy patients earlystage tnbc improvement seen adding keytruda neoadjuvant chemotherapy observed regardless pdl expression dual primary endpoint eventfreesurvival efs median followup months keytruda regimen reduced risk progression neoadjuvant phase recurrence adjuvant phase compared chemotherapyplacebo regimen merck continues discuss interim analysis data keynote regulatory authorities keytruda breast cancer clinical development program encompasses several internal external collaborative studies february merck announced pivotal phase keynote trial investigating keytruda combination chemotherapy met one dual primary endpoints progressionfree survival pfs patients metastatic triplenegative breast cancer mtnbc whose tumors expressed pdl cps based interim analysis conducted independent data monitoring committee dmc firstline treatment keytruda combination chemotherapy nabpaclitaxel paclitaxel gemcitabinecarboplatin demonstrated statistically significant clinically meaningful improvement pfs compared chemotherapy alone patients based recommendation dmc trial continue without changes evaluate dual primary endpoint overall survival os may merck announced phase keynote trial evaluating keytruda monotherapy second thirdline treatment patients metastatic tnbc meet prespecified primary endpoint superior os compared chemotherapy endpoints formally tested per study protocol primary endpoint os met june merck announced full results pivotal phase keynote trial evaluating keytruda monotherapy combination chemotherapy firstline treatment advanced gastric gastroesophageal junction adenocarcinoma monotherapy arm study keytruda met primary endpoint demonstrating noninferiority chemotherapy current standard care os patients whose tumors expressed pdl cps combination arm keynote keytruda plus chemotherapy found statistically superior os cps cps pfs cps compared chemotherapy alone results presented asco annual meeting september fda approved keytruda thirdline treatment previously treated patients recurrent locally advanced metastatic gastric gastroesophageal junction cancer whose tumors express pdl cps determined fdaapproved test keynote potential confirmatory trial accelerated thirdline approval addition keynote additional firstline phase table contents studies mercks gastric clinical program include keynote keynote well keynote neoadjuvant adjuvant treatment setting january merck announced phase keynote trial investigating keytruda combination chemotherapy met one dual primary endpoints pfs firstline treatment patients extensive stage sclc final analysis study also improvement os patients treated keytruda combination chemotherapy compared chemotherapy alone however os results meet statistical significance per prespecified statistical plan results presented upcoming medical meeting discussed regulatory authorities lynparza oral parp inhibitor currently approved certain types advanced ovarian breast pancreatic cancers codeveloped multiple cancer types part collaboration astrazeneca see note consolidated financial statements lynparza review eu firstline maintenance monotherapy patients gbrcam metastatic pancreatic cancer whose disease progressed following firstline platinumbased chemotherapy lynparza approved indication fda december based results phase polo trial decision european medicines agency ema expected second half january fda accepted supplemental nda lynparza combination bevacizumab maintenance treatment women advanced ovarian cancer whose disease showed complete partial response firstline treatment platinumbased chemotherapy bevacizumab based results pivotal phase paola trial pdufa date set second quarter indication also review eu january fda accepted priority review supplemental nda lynparza treatment patients metastatic castrationresistant prostate cancer mcrpc deleterious suspected deleterious germline somatic homologous recombination repair hrr gene mutations progressed following prior treatment new hormonal agent based positive results phase profound trial pdufa date set second quarter indication also review eu june merck astrazeneca presented full results phase solo trial evaluated lynparza compared chemotherapy treatment platinumsensitive relapsed patients gbrcam advanced ovarian cancer received two prior lines chemotherapy results trial showed statisticallysignificant clinicallymeaningful improvement objective response rate orr lynparza arm compared chemotherapy arm key secondary endpoint pfs also significantly increased lynparza arm compared chemotherapy arm results presented asco annual meeting mk selumetinib mek inhibitor codeveloped part strategic collaboration astrazeneca see note consolidated financial statements selumetinib priority review fda potential new medicine pediatric patients aged three years older neurofibromatosis type nf symptomatic inoperable plexiform neurofibromas regulatory submission based positive results national cancer institute cancer therapy evaluation programsponsored sprint phase stratum trial pdufa date set second quarter v review japan initial indication females prevention certain hpvrelated diseases precursors february fda accepted priority review supplemental bla gardasil prevention certain head neck cancers caused vaccinetype hpv females males years age fda set pdufa date june addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed lynparza addition indications review discussed phase development combination keytruda treatment nsclc lenvima orally available tyrosine kinase inhibitor currently approved certain types thyroid cancer hcc combination certain patients rcc codeveloped part strategic collaboration eisai see note consolidated financial statements pursuant agreement companies jointly table contents initiate clinical studies evaluating keytrudalenvima combination six types cancer endometrial cancer nsclc hcc hnscc bladder cancer melanoma well basket trial targeting multiple cancer types fda granted breakthrough therapy designation keytruda combination lenvima potential treatment patients advanced andor metastatic rcc potential treatment patients unresectable hcc amenable locoregional treatment mk gefapixant selective nonnarcotic orallyadministered pxreceptor antagonist investigated phase trials treatment refractory chronic cough phase trial treatment women endometriosisrelated pain mk vericiguat sgc stimulator potential treatment patients worsening chronic heart failure developed part worldwide strategic collaboration merck bayer see note consolidated financial statements vericiguat studied patients suffering chronic heart failure reduced ejection fraction phase clinical trial chronic heart failure preserved ejection fraction phase clinical trial november merck announced phase victoria study evaluating efficacy safety vericiguat met primary efficacy endpoint vericiguat reduced risk composite endpoint heart failure hospitalization cardiovascular death patients worsening chronic heart failure reduced ejection fraction compared placebo given combination available heart failure therapies results victoria study presented upcoming medical meeting v investigational polyvalent conjugate vaccine prevention pneumococcal disease june merck initiated first phase study adult population prevention invasive pneumococcal disease currently six phase adult studies ongoing including studies healthy adults years age older adults risk factors pneumococcal disease infected hiv recipients allogeneic hematopoietic stem cell transplant october merck began first phase study pediatric population currently eight studies ongoing including studies healthy infants children afflicted sickle cell disease v received breakthrough therapy designation fda prevention invasive pneumococcal disease caused vaccine serotypes pediatric patients weeks years age adults company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases diabetes metabolic diseases infectious diseases neurosciences pain respiratory diseases vaccines acquired inprocess research development connection business acquisitions company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date table contents circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded iprd impairment charges within research development expenses million million million respectively see note consolidated financial statements additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent transactions described merck actively monitoring landscape growth opportunities meet companys strategic criteria april merck acquired immune design latestage immunotherapy company employing nextgeneration vivo approaches enable bodys immune system fight disease million cash transaction accounted acquisition business merck recognized intangible assets iprd million cash million net assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach actual cash flows likely different assumed july merck acquired peloton clinicalstage biopharmaceutical company focused development novel small molecule therapeutic candidates targeting hypoxiainducible factor hif treatment patients cancer nononcology diseases pelotons lead candidate mk formerly pt novel oral hif inhibitor latestage development renal cell carcinoma merck made upfront payment billion cash additionally former peloton shareholders eligible receive million upon us regulatory approval million upon first commercial sale united states billion salesbased milestones transaction accounted acquisition asset merck recorded cash million deferred tax liabilities million net liabilities million acquisition date research development expenses million related transaction january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused kinase inhibitor discovery development treatment patients cancer diseases billion arqules lead investigational candidate mk formerly arq novel oral brutons tyrosine kinase btk inhibitor currently phase dose expansion study treatment bcell malignancies company process determining preliminary fair value assets acquired liabilities assumed total consideration transferred transaction accounted acquisition business capital expenditures capital expenditures billion billion billion expenditures united states billion billion billion increased capital expenditures reflect investment new capital projects focused primarily increasing manufacturing capacity mercks key products previously announced company plans invest billion new capital projects depreciation expense billion billion billion billion billion billion related locations united states total depreciation expense included accelerated depreciation million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders table contents selected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion compared billion reflecting stronger operating performance increased accounts receivable factoring discussed cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders cash used investing activities billion compared cash provided investing activities billion change driven primarily lower proceeds sales securities investments acquisitions antelliq peloton higher capital expenditures partially offset lower purchases securities investments cash used financing activities billion compared billion lower use cash financing activities driven primarily proceeds issuance debt lower purchases treasury stock reflecting accelerated share repurchase asr program discussed well lower payments debt partially offset repayment shortterm borrowings higher dividends paid shareholders lower proceeds exercise stock options company accounts receivable factoring agreements financial institutions certain countries sell accounts receivable see note consolidated financial statements company factored billion billion accounts receivable fourth quarter respectively factoring arrangements reduced outstanding accounts receivable cash received financial institutions reported within operating activities consolidated statement cash flows certain factoring arrangements ease administration company collect customer payments related factored receivables remits financial institutions december company collected million behalf financial institutions remitted january net cash flows collections reported financing activities consolidated statement cash flows companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits transition tax related enactment tcja milestone payments related collaborations leases includes future inventory purchases company committed connection certain divestitures december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made connection enactment tcja company required pay onetime transition tax company elected pay period eight years permitted tcja see note consolidated financial statements reflects payments collaborative agreements salesbased milestones achieved therefore deemed contractual obligations paid january see note consolidated financial statements amounts exclude reasonably certain lease renewals yet executed see note consolidated financial statements table contents purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts include contingent milestone payments related collaborative arrangements acquisitions considered contractual obligations successful achievement developmental regulatory approval commercial milestones december company recognized liabilities contingent salesbased milestone payments related collaborations astrazeneca eisai bayer payment remains subject achievement related sales milestone aggregating billion see note consolidated financial statements excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion longterm debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million us pension plans million international pension plans million postretirement benefit plans march company issued billion principal amount senior unsecured notes consisting million notes due billion notes due billion notes due billion notes due company used net proceeds offering billion general corporate purposes including repayment outstanding commercial paper borrowings december company exercised makewhole provision billion notes due repaid debt november company launched tender offers certain outstanding notes debentures company paid million aggregate consideration applicable purchase price together accrued interest redeem million principal amount debt validly tendered connection tender offers company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility march company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november mercks board directors declared quarterly dividend per share companys outstanding common stock paid january january board directors declared quarterly dividend per share companys common stock second quarter payable april october mercks board directors authorized purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions company spent billion purchase million shares common stock treasury addition company received million shares settlement asr agreements discussed december companys remaining share repurchase authorization billion company purchased billion billion common stock respectively authorized share repurchase programs table contents october company entered asr agreements two thirdparty financial institutions dealers asr agreements merck agreed purchase billion mercks common stock total initial delivery million shares mercks common stock based thencurrent market price made dealers merck payments billion made merck dealers october funded existing cash investments well shortterm borrowings upon settlement asr agreements april merck received additional million shares determined average daily volume weightedaverage price mercks common stock term asr program less negotiated discount bringing total shares received merck program million financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened table contents currency exposures company december income taxes would declined approximately million million respectively company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows economy argentina determined hyperinflationary consequently accordance us gaap company began remeasuring monetary assets liabilities operations earnings impact companys results immaterial company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income loss oci remain accumulated comprehensive income loss aoci either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded component changes fair value excluded components recognized oci company recognizes earnings initial value excluded component straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value table contents mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions dispositions determine whether transactions accounted acquisitions disposals assets businesses company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition fair values intangible assets including acquired iprd determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability table contents remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate company determines transaction accounted acquisition business transaction accounted asset acquisition rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense contingent consideration recognized acquisition date instances product development milestones recognized upon achievement salesbased milestones recognized milestone deemed probable company achieved revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment businesses within companys healthcare services segment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts united states sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year us provision aggregate customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges table contents company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued company continually monitors provision aggregate customer discounts material adjustments estimates associated aggregate customer discount provision summarized information changes aggregate customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside united states variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales outside united states returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products including keytruda longer payment terms days outside united states payment terms typically days days although certain markets longer payment terms distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing table contents product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide abovementioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities table contents assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension plans totaled million million million net periodic benefit credit postretirement benefit plans million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension plans largely attributable changes discount rate affecting net loss amortization company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data current market conditions actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range decrease reflects lower expected asset returns modest shift asset allocation company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension table contents postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized market related value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed streamline companys cost structure result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing termination costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within cost sales selling general administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price company concludes table contents likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangible assets excluding iprd initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations impairments investments company reviews investments marketable debt securities impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments marketable debt securities including duration extent fair value less cost changes fair value considered temporary reported net tax oci otherthantemporary impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely table contents realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements recently issued accounting standards discussion recently issued accounting standards see note consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income taxes taxes income net income less net loss income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive loss income net taxes net unrealized loss gain derivatives net reclassifications net unrealized gain loss investments net reclassifications benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive income net taxes cash dividends declared common stock per share treasury stock shares purchased acquisition valle sa net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc adoption new accounting standards comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net loss attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net loss attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges charge acquisition peloton therapeutics inc charge future payments related collaboration license options provisional charge onetime transition tax related enactment us tax legislation deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments acquisition antelliq corporation net cash acquired acquisition peloton therapeutics inc net cash acquired acquisitions net cash acquired net cash used provided investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents restricted cash net increase decrease cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year includes million restricted cash january included assets cash cash equivalents restricted cash end year includes million restricted cash december included assets see note accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients company recently sold certain businesses healthcare services segment process divesting remaining businesses alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded planned spinoff womens health legacy brands biosimilars new company february merck announced intention spinoff products womens health trusted legacy brands biosimilars businesses new yettobenamed independent publicly traded company newco distribution newcos publicly traded stock company shareholders distribution expected qualify taxfree company shareholders us federal income tax purposes legacy brands included transaction consist dermatology pain respiratory select cardiovascular products including zetia vytorin well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned newco development capabilities initially focused latestage development lifecycle management expected time develop research capabilities selected therapeutic areas spinoff expected completed first half subject market certain conditions subsequent spinoff historical results womans health legacy brands biosimilars businesses reflected discontinued operations companys consolidated financial statements summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis table contents acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired inprocess research development iprd alternative future use charged expense contingent consideration recognized acquisition date foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost net realizable value cost substantial majority us pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt securities classified availableforsale reported fair value fair values companys investments marketable debt securities determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci company considers available evidence evaluating potential impairments investments marketable debt securities including duration extent fair value less cost thantemporary impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt securities included income expense net investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net table contents investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net revenue recognition january company adopted asu revenue contracts customers subsequent amendments asc new guidance using modified retrospective method comparative information prior periods restated continues reported accounting standards effect periods recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allows companies recognize revenue sales vaccines us government stockpiles even though sales might meet criteria revenue recognition accounting guidance businesses within companys healthcare services segment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts united states sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year us provision aggregate customer discounts covering chargebacks rebates billion billion billion chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued accrued balances relative provisions chargebacks rebates included accounts table contents receivable accrued current liabilities million billion respectively december million billion respectively december outside united states variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others outside united states returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products including keytruda longer payment terms days outside united states payment terms typically days days although certain markets longer payment terms depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion respectively software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development costs included property plant equipment addition company capitalizes certain costs incurred implement cloud computing arrangement considered service agreement included assets capitalized software costs amortized beginning software project substantially complete asset ready intended use capitalized software costs associated projects amortized years including companys ongoing multi year implementation enterprisewide resource planning system million million net accumulated amortization december respectively capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangibles acquired intangibles include products product rights licenses trade names patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may table contents recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales transaction accounted acquisition business fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings significant events increase decrease probability achieving development regulatory milestones increase decrease projected cash flows result corresponding increases decreases fair values related contingent consideration obligations transaction accounted acquisition asset rather business contingent consideration recognized acquisition date instances product development milestones recognized upon achievement salesbased milestones recognized milestone deemed probable company achieved research development research development expensed incurred nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration research development expenses also include upfront milestone payments related asset acquisitions licensing transactions involving clinical development programs yet received regulatory approval collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners merck principal sales transactions third parties company recognizes sales cost sales selling general administrative expenses gross basis profit sharing amounts pays collaborative partners recorded within cost sales collaborative partner principal sales transactions third parties company records profit sharing amounts received collaborative partners alliance revenue within sales alliance revenue recorded net cost sales includes adjustment share commercialization costs partners accordance collaboration agreement adjustment determined comparing commercialization costs merck incurred directly reported within selling general administrative expenses costs collaborative partner incurred research development costs merck incurs related collaborations recorded within research development expenses cost reimbursements collaborative partner payments received collaborative partner share costs pursuant terms collaboration agreements recorded increases decreases research development expenses table contents addition terms collaboration agreements may require company make payments based upon achievement certain developmental regulatory approval commercial milestones upfront milestone payments payable merck collaborative partners prior regulatory approval expensed incurred included research development expenses payments due collaborative partners upon subsequent regulatory approval capitalized amortized estimated useful life corresponding intangible asset cost sales provided future cash flows support amounts capitalized salesbased milestones payable merck collaborative partners accrued capitalized subject cumulative amortization catchup probable achieved amortization catchup calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized cost sales remaining useful life subject impairment testing sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income company accounts tax effects tax global intangible lowtaxed income gilti certain foreign subsidiaries income tax provision period tax arises use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards february financial accounting standards board fasb issued new accounting guidance accounting reporting leases asu subsequently issued several updates new guidance asc new leasing guidance new leasing guidance requires table contents lessees recognize rightofuse asset lease liability leases leases meet definition shortterm lease leases classified either operating finance operating leases result straightline expense income statement similar previous operating leases finance leases result expense recognized earlier years lease term similar previous capital leases company adopted new standard january using modified retrospective approach merck elected transition method allows application standard adoption date rather beginning earliest comparative period presented financial statements company also elected available practical expedients upon adoption company recognized billion additional assets related liabilities consolidated balance sheet see note adoption new leasing guidance impact companys consolidated statements income cash flows april fasb issued new guidance accounting costs incurred implement cloud computing arrangement considered service arrangement new guidance requires capitalization costs aligning accounting costs associated developing obtaining internaluse software company adopted new standard third quarter using prospective application eligible costs immaterial august fasb issued new guidance modifying disclosure requirements employers sponsor defined benefit pension postretirement plans new guidance removes disclosures longer considered cost beneficial clarifies specific requirements certain disclosures adds disclosure requirements identified relevant company elected early adopt new guidance retrospective basis resulting minor changes employee benefit plan disclosures see note also august fasb issued new guidance fair value measurements adds removes modifies certain disclosure requirements company elected early adopt new guidance resulting minor changes fair value disclosures see note recently issued accounting standards yet adopted june fasb issued new guidance accounting credit losses financial instruments new guidance introduces expected loss model estimating credit losses replacing incurred loss model new guidance also changes impairment model availableforsale debt securities requiring use allowance record estimated credit losses subsequent recoveries company adopted new guidance effective january impact companys consolidated financial statements upon adoption november fasb issued new guidance collaborative arrangements intended reduce diversity practice clarifying whether certain transactions collaborative arrangement participants accounted revenue recognition guidance asc company adopted new guidance effective january result minor changes footnote presentation information related companys collaborative arrangements december fasb issued amended guidance accounting reporting income taxes guidance intended simplify accounting income taxes removing exceptions related certain intraperiod tax allocations deferred tax liabilities clarifying guidance primarily related evaluating stepup tax basis goodwill business combination reflecting enacted changes tax laws rates annual effective tax rate amended guidance effective interim annual periods early adoption permitted application amendments new guidance applied retrospective basis modified retrospective basis cumulativeeffect adjustment retained earnings prospectively depending amendment company currently evaluating impact adoption consolidated financial statements january fasb issued new guidance intended clarify certain interactions accounting standards related equity securities equity method investments certain derivatives guidance addresses accounting transition equity method accounting measuring certain purchased options forward contracts acquire investments new guidance effective interim annual periods applied prospectively early adoption permitted company currently evaluating impact adoption consolidated financial statements table contents acquisitions divestitures research collaborations license agreements company continues pursue acquisition businesses establishment external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share arrangements contingent upon occurrence certain future events linked success asset development company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results recently completed transaction january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused kinase inhibitor discovery development treatment patients cancer diseases billion arqules lead investigational candidate mk formerly arq novel oral brutons tyrosine kinase btk inhibitor currently phase dose expansion study treatment bcell malignancies company process determining preliminary fair value assets acquired liabilities assumed total consideration transferred transaction accounted acquisition business transactions july merck acquired peloton therapeutics inc peloton clinicalstage biopharmaceutical company focused development novel small molecule therapeutic candidates targeting hypoxiainducible factor hif treatment patients cancer nononcology diseases pelotons lead candidate mk formerly pt novel oral hif inhibitor latestage development renal cell carcinoma merck made upfront payment billion cash additionally former peloton shareholders eligible receive million upon us regulatory approval million upon first commercial sale united states billion salesbased milestones transaction accounted acquisition asset merck recorded cash million deferred tax liabilities million net liabilities million acquisition date research development expenses million related transaction april merck acquired antelliq corporation antelliq leader digital animal identification traceability monitoring solutions solutions help veterinarians farmers pet owners gather critical data improve management health wellbeing livestock pets merck paid billion acquire outstanding shares antelliq spent billion repay antelliqs debt transaction accounted acquisition business estimated fair value assets acquired liabilities assumed antelliq follows millions april cash cash equivalents accounts receivable inventories property plant equipment identifiable intangible assets useful lives ranging years deferred income tax liabilities assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair values identifiable intangible assets relate primarily trade names determined using income approach future net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated animal health segment goodwill deductible tax purposes table contents companys results include eight months activity antelliq company incurred million transaction costs directly related acquisition antelliq consisting largely advisory fees reflected selling general administrative expenses also april merck acquired immune design latestage immunotherapy company employing nextgeneration vivo approaches enable bodys immune system fight disease million cash transaction accounted acquisition business merck recognized intangible assets iprd million cash million net assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach actual cash flows likely different assumed transactions company recorded aggregate charge million within cost sales conjunction termination collaboration agreement entered samsung bioepis co ltd samsung insulin glargine charge reflects termination payment million represents reimbursement fees previously paid samsung merck agreement plus interest well release mercks ongoing obligations agreement charge also included fixed asset abandonment charges million inventory writeoffs million well related costs million termination agreement impact companys collaboration samsung june merck acquired viralytics limited viralytics australian publicly traded company focused oncolytic immunotherapy treatments range cancers aud million million transaction provided merck full rights v formerly cva viralyticss investigational oncolytic immunotherapy v based viralyticss proprietary formulation oncolytic virus coxsackievirus type shown preferentially infect kill cancer cells v currently evaluated multiple clinical trials intratumoral intravenous agent including combination keytruda previous agreement merck viralytics study investigating use keytruda v combination melanoma prostate lung bladder cancers transaction accounted acquisition asset merck recorded net assets million primarily cash acquisition date research development expenses million related transaction future contingent payments associated acquisition march merck eisai co ltd eisai entered strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discovered eisai see note transactions october merck acquired rigontec gmbh rigontec leader accessing retinoic acidinducible gene pathway part innate immune system novel distinct approach cancer immunotherapy induce immediate longterm antitumor immunity rigontecs lead candidate mk formerly rgt development treatment patients various tumors terms agreement merck made upfront cash payment million million may make additional contingent payments million million related achievement research milestones regulatory approvals million related achievement commercial targets transaction accounted acquisition asset upfront payment reflected within research development expenses july merck astrazeneca plc astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types see note march merck acquired controlling interest valle sa valle leading privately held producer animal health products brazil valle extensive portfolio products spanning parasiticides antiinfectives vaccines include products livestock horses companion animals terms agreement merck acquired shares valle million total purchase price million placed escrow pending resolution certain contingent items transaction accounted acquisition business merck recognized intangible assets million related currently marketed products net deferred tax liabilities million net assets million noncontrolling interest million addition company recorded liabilities million contingencies identified acquisition date corresponding table contents indemnification assets million representing amounts reimbursed merck contingent liabilities paid excess consideration transferred fair value net assets acquired million recorded goodwill goodwill allocated animal health segment deductible tax purposes estimated fair values identifiable intangible assets related currently marketed products determined using income approach actual cash flows likely different assumed intangible assets related currently marketed products amortized estimated useful lives years fourth quarter merck acquired additional interest valle million reduced noncontrolling interest related valle remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey remicade lost market exclusivity major european markets company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners parties arrangements active participants exposed significant risks rewards dependent commercial success activities collaboration mercks significant collaborative arrangements discussed astrazeneca july merck astrazeneca plc astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types lynparza oral poly adpribose polymerase parp inhibitor currently approved certain types ovarian breast cancer companies jointly developing commercializing lynparza monotherapy combination trials potential medicines independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda imfinzi companies also jointly develop commercialize astrazenecas selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently developed multiple indications terms agreement astrazeneca merck share development commercialization costs lynparza selumetinib monotherapy nonpdlpd combination therapy opportunities gross profits lynparza selumetinib product sales generated monotherapies combination therapies shared equally merck fund development commercialization costs keytruda combination lynparza selumetinib astrazeneca fund development commercialization costs imfinzi combination lynparza selumetinib astrazeneca principal lynparza sales transactions merck records share lynparza product sales net cost sales commercialization costs alliance revenue share development costs associated collaboration part research development expenses reimbursements received astrazeneca research development expenses recognized reductions research development costs part agreement merck made upfront payment astrazeneca billion made payments million multiyear period certain license options million paid december million paid december million paid december company recorded aggregate charge billion research development expenses related upfront payment license option payments addition agreement provides additional contingent payments merck astrazeneca related successful achievement salesbased regulatory milestones merck determined probable annual sales lynparza future would trigger million salesbased milestone payment merck astrazeneca accordingly merck recorded table contents million liability corresponding increase intangible asset related lynparza prior merck accrued salesbased milestone payments aggregating million million million paid astrazeneca respectively remainder million paid january potential future salesbased milestone payments billion yet accrued deemed company probable time lynparza received regulatory approval european union eu monotherapy treatment certain adult patients advanced breast cancer monotherapy maintenance treatment certain adult patients brcamutated advanced ovarian cancer approvals triggered million capitalized milestone payment merck astrazeneca lynparza received regulatory approvals triggering capitalized milestone payments million aggregate merck astrazeneca potential future regulatory milestone payments billion remain agreement intangible asset balance related lynparza includes capitalized salesbased regulatory milestone payments million december included intangibles net consolidated balance sheet amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue cost sales selling general administrative research development december receivables astrazeneca included current assets payables astrazeneca included accrued current liabilities payables astrazeneca included noncurrent liabilities represents amortization capitalized milestone payments amount includes billion related upfront payment license option payments includes accrued milestone payments eisai march merck eisai announced strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discovered eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination mercks keytruda eisai records lenvima product sales globally eisai principal lenvima sales transactions merck eisai share gross profits equally merck records share lenvima product sales net cost sales commercialization costs alliance revenue expenses incurred codevelopment including studies evaluating lenvima monotherapy shared equally two companies reflected research development expenses agreement merck made upfront payment eisai million make payments million certain option rights million paid march million expected paid march million expected paid march company recorded aggregate charge billion research development expenses related upfront payment future option payments addition agreement provides additional contingent payments merck eisai related successful achievement salesbased regulatory milestones merck determined probable annual sales lenvima future would trigger salesbased milestone payments merck eisai aggregating million accordingly merck recorded million liabilities corresponding increases intangible asset related lenvima merck accrued salesbased milestone payments aggregating million related lenvima amounts million paid table contents eisai additional million paid january potential future salesbased milestone payments billion yet accrued deemed company probable time lenvima received regulatory approvals triggering capitalized milestone payments million aggregate merck eisai potential future regulatory milestone payments million remain agreement intangible asset balance related lenvima includes capitalized salesbased regulatory milestone payments million december included intangibles net consolidated balance sheet amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue cost sales selling general administrative research development december receivables eisai included current assets payables eisai included accrued current liabilities payables eisai included noncurrent liabilities represents amortization capitalized milestone payments amount includes billion related upfront payment option payments includes accrued milestone future option payments bayer ag company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas approved treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension two companies implemented joint development commercialization strategy collaboration also includes clinical development bayers vericiguat phase trials worsening heart failure well optin rights earlystage sgc compounds development bayer merck turn made available earlystage sgc compounds similar terms agreement bayer leads commercialization adempas americas merck leads commercialization rest world vericiguat potential optin products bayer lead commercialization rest world merck lead americas products candidates included agreement companies share development costs profits sales right copromote territories lead revenue adempas includes sales mercks marketing territories well mercks share profits sale adempas bayers marketing territories addition agreement provides additional contingent payments merck bayer related successful achievement salesbased milestones merck determined probable annual worldwide sales adempas future would trigger million salesbased milestone payment merck bayer accordingly merck recorded million liability corresponding increase intangible asset related adempas company made million milestone payment bayer accrued merck deemed payment probable additional million potential future salesbased milestone payment yet accrued deemed company probable time intangible asset balance related adempas includes acquired intangible asset balance well capitalized salesbased milestone payments million december included intangibles net consolidated balance sheet amount amortized estimated useful life supported projected future cash flows subject impairment testing table contents summarized financial information related collaboration follows years ended december net product sales recorded merck mercks profit share sales bayers marketing territories total sales cost sales selling general administrative research development december receivables bayer included current assets payables bayer included noncurrent liabilities includes amortization intangible assets represents accrued milestone payment restructuring early merck approved new global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs include actions associated planned spinoff newco company continues evaluate global footprint overall operating model subsequently identified additional actions restructuring program could identify actions time actions currently contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion company estimates approximately cumulative pretax costs result cash outlays primarily related employee separation expense facility shutdown costs approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects record charges approximately million related restructuring program actions previous global restructuring programs substantially completed company recorded total pretax costs million million million related restructuring program activities segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated costs depreciation total year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recording accelerated depreciation revised useful life site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes asset abandonment facility shutdown related costs well pretax gains losses resulting sales facilities related assets additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note sharebased compensation following table summarizes charges spending relating restructuring program activities separation accelerated costs depreciation total restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december remaining cash outlays expected substantially completed end table contents financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year table contents company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aoci either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded component changes fair value excluded components recognized oci company recognizes earnings initial value excluded component straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci effects companys net investment hedges oci consolidated statement income shown amount pretax gain loss recognized amount pretax gain loss recognized income expense net amounts excluded comprehensive income effectiveness testing years ended december net investment hedging relationships foreign exchange contracts eurodenominated notes amounts reclassified aoci income related sale subsidiary interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows table contents table presents location amounts recorded consolidated balance sheet related cumulative basis adjustments fair value hedges december cumulative amount fair value hedging adjustment increase decrease included carrying amount hedged liabilities carrying amount balance sheet line item hedged item included loans payable current portion longterm debt longterm debt presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts accrued current liabilities interest rate swap contracts noncurrent liabilities foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current assets foreign exchange contracts accrued current liabilities noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amounts subject offset master netting arrangements offset consolidated balance sheet cash collateral received net amounts table contents table provides information regarding location amount pretax gains losses derivatives designated fair value cash flow hedging relationships sales income expense net comprehensive income loss years ended december financial statement line items effects fair value cash flow hedges recorded gain loss fair value hedging relationships interest rate swap contracts hedged items derivatives designated hedging instruments impact cash flow hedging relationships foreign exchange contracts amount gain loss recognized oci derivatives decrease increase sales result aoci reclassifications interest rate contracts amount gain recognized income expense net derivatives amount loss recognized oci derivatives interest expense component income expense net table provides information regarding income statement effects derivatives designated hedging instruments amount derivative pretax gain loss recognized income years ended december income statement caption derivatives designated hedging instruments foreign exchange contracts income expense net foreign exchange contracts sales derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates derivative contracts serve economic hedges forecasted transactions december company estimates million pretax net unrealized gains derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized amortized fair amortized fair cost gains losses value cost gains losses value commercial paper corporate notes bonds us government agency securities assetbacked securities foreign government bonds mortgagebacked securities total debt securities publicly traded equity securities total debt publicly traded equity securities unrealized net gains recognized income expense net equity securities still held december million unrealized net losses recognized income expense net equity securities still held december million december company also million million respectively equity investments without readily determinable fair values included assets company recognized unrealized gains million million respectively income expense net certain equity investments based favorable observable price changes transactions involving similar investments investee addition company recognized unrealized losses million million respectively income expense net related certain investments based unfavorable observable price changes cumulative unrealized gains cumulative unrealized losses based observable prices changes investments equity investments without readily determinable fair values million million respectively availableforsale debt securities included shortterm investments totaled million december remaining debt securities million mature within five years december debt securities pledged collateral fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using level level level total level level level total assets investments commercial paper corporate notes bonds assetbacked securities us government agency securities foreign government bonds publicly traded equity securities assets us government agency securities corporate notes bonds assetbacked securities mortgagebacked securities publicly traded equity securities derivative assets forward exchange contracts purchased currency options interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts interest rate swaps written currency options total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily auto loan credit card student loan receivables weightedaverage lives primarily years less investments included assets restricted use including payment benefits employee benefit plans fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant december cash cash equivalents billion include billion cash equivalents would considered level fair value hierarchy table contents contingent consideration summarized information changes liabilities contingent consideration associated business acquisitions follows fair value january changes estimated fair value additions payments fair value december recorded cost sales research development expenses income expense net includes cumulative translation adjustments balance december includes million recorded current liability amounts expected paid within next months december million million respectively liabilities relate termination spmsd joint venture part termination merck recorded liability contingent future royalty payments net sales merck products previously sold joint venture december fair value liability determined utilizing estimated amount timing projected cash flows riskadjusted discount rate used present value cash flows changes estimated fair value liabilities contingent consideration largely attributable increases liabilities recorded connection termination sanofi pasteur msd spmsd joint venture increases partially offset reversal liability related discontinuation program obtained connection acquisition smartcells see note payments contingent consideration years relate spmsd termination liabilities described payments contingent consideration also include million related achievement clinical development milestone mk gefapixant program obtained connection acquisition afferent pharmaceuticals fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales united states europe china primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor global economic conditions including volatility associated international sovereign economies associated impacts financial markets business companys customers largest accounts receivable balances mckesson corporation amerisourcebergen corporation cardinal health inc represented aggregate approximately total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales company accounts receivable factoring agreements financial institutions certain countries sell accounts receivable company expanded factoring arrangements china entered factoring agreements sell accounts receivable companys major us distributors company factored table contents billion billion accounts receivable fourth quarter respectively factoring arrangements reduced outstanding accounts receivable cash received financial institutions reported within operating activities consolidated statement cash flows certain factoring arrangements ease administration company collect customer payments related factored receivables remits financial institutions december company collected million behalf financial institutions reflected restricted cash current assets related obligation remit cash within accrued current liabilities company remitted cash financial institutions january net cash flows relating collections reported financing activities consolidated statement cash flows costs factoring accounts receivable de minimis derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty cash collateral received company various counterparties million million december respectively obligation return collateral recorded accrued current liabilities cash collateral advanced company counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost decrease increase lifo cost recognized inventories assets inventories valued lifo method comprised approximately billion billion december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches table contents goodwill intangibles following table summarizes goodwill activity segment pharmaceutical animal health total balance january acquisitions impairments balance december acquisitions impairments balance december includes cumulative translation adjustments goodwill balances certain adjustments accumulated goodwill impairment losses december million million respectively additions goodwill within animal health segment primarily relate acquisition antelliq see note impairments goodwill within nonreportable segments relate certain businesses within healthcare services segment intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights licenses iprd trade names acquired intangibles include products product rights licenses trade names patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives companys significant acquired intangibles net basis related human health marketed products included products product rights december include zerbaxa billion implanonnexplanon million gardasilgardasil million dificid million bridion million sivextro million simponi million additionally company billion acquired intangibles related animal health marketed products december companys significant intangible assets included licenses december include lenvima million lynparza million result collaborations eisai astrazeneca see note increase trade names reflects billion intangibles acquired antelliq acquisition see note company intangible asset related adempas result collaboration bayer see note carrying value million december reflected table company recorded impairment charges related marketed products intangibles million within cost sales amount million related sivextro product treatment acute bacterial skin skin structure infections caused designated susceptible grampositive organisms part reorganization reprioritization internal sales force company made decision cease promotion sivextro us market end decision resulted reduced cash flow projections sivextro indicated sivextro intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible table contents asset related sivextro compared related carrying value resulted impairment charge noted company recorded impairment charges related marketed products intangibles million amount million related intron treatment certain types cancers sales intron adversely affected availability new therapeutic options sales intron united states eroded rapidly previously anticipated company led changes cash flow assumptions intron revisions cash flows indicated intron intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related intron compared related carrying value resulted impairment charge noted remaining charges relate impairment customer relationship tradename developed technology intangibles certain businesses healthcare services segment iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life asset begin amortization company recorded million iprd impairment charges within research development expenses amount million relates writeoff intangible asset balance programs obtained connection acquisition iomet pharma ltd following review clinical trial results conducted merck along external clinical trial results similar compounds discontinuation clinical development program resulted reversal related liability contingent consideration million company recorded million iprd impairment charges amount million relates writeoff remaining intangible asset balance program obtained connection smartcells acquisition following decision terminate program due product development issues discontinuation clinical development program resulted reversal related liability contingent consideration million see note company recorded million iprd impairment charges amount million resulted strategic decision discontinue development investigational combination regimens mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment chronic hepatitis c virus hcv infection decision made based review available phase efficacy data consideration evolving marketplace growing number treatment options available patients chronic hcv infection including zepatier marketed company treatment adult patients chronic hcv infection result decision company recorded iprd impairment charge writeoff remaining intangible asset related uprifosbuvir iprd impairment charges also include charge million writeoff intangible asset related verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace resulting decision february stop phase study evaluating verubecestat people prodromal alzheimers disease decision stop study followed recommendation external data monitoring committee edmc assessed overall benefitrisk interim safety analysis edmc concluded unlikely positive benefitrisk could established trial continued iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense recorded within cost sales billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion table contents loans payable longterm debt leases loans payable loans payable december included billion notes due billion commercial paper million longdated notes subject repayment option holders loans payable december included billion commercial paper million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively longterm debt longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due debentures due notes due debentures due debentures due notes due floatingrate notes due presented table includes million million december respectively borrowings variable rates resulted effective interest rates respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices march company issued billion principal amount senior unsecured notes consisting million notes due billion notes due billion notes due billion notes due company used net proceeds offering billion general corporate purposes including repayment outstanding commercial paper borrowings table contents effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply covenants december company compliance covenants aggregate maturities longterm debt next five years follows billion billion billion billion billion company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility leases discussed note january merck adopted new guidance accounting reporting leases company operating leases primarily manufacturing facilities research development facilities corporate offices employee housing vehicles certain equipment permitted transition guidance asc company elected package practical expedients among provisions allowed company carry forward historical lease classifications company determines arrangement lease inception evaluating contracts embedded leases company exercises judgment determine explicit implicit identified asset contract merck controls use asset embedded leases primarily associated contract manufacturing organizations immaterial asc transition guidance merck elected hindsight practical expedient determine lease term existing leases permits companies consider available information prior effective date new guidance actual likely exercise options extend terminate lease lease term includes options extend terminate lease reasonably certain merck exercise option real estate leases facilities average remaining lease term eight years include options extend leases four years applicable vehicle leases generally effect four years company made accounting policy election record shortterm leases leases initial term months less balance sheet however merck currently shortterm leases lease expense operating lease payments recognized straightline basis term lease operating lease assets liabilities recognized based present value lease payments lease term since companys leases readily determinable implicit discount rate company uses incremental borrowing rate calculate present value lease payments asset class quarterly basis updated incremental borrowing rate determined based average remaining lease term asset class companys pretax cost debt term updated rates asset class applied prospectively new leases practical expedient company made accounting policy election asset classes separate lease components eg payments rent real estate taxes insurance costs nonlease components eg commonarea maintenance costs event agreement contains merck includes lease nonlease components purposes calculating rightofuse asset related lease liability nonlease components fixed vehicle leases employee housing company applies portfolio approach effectively account operating lease assets liabilities certain companys lease agreements contain variable lease payments adjusted periodically inflation actual operating expense true ups compared estimated amounts however amounts immaterial sublease income activity related sale leaseback transactions immaterial mercks lease agreements contain material residual value guarantees material restrictive covenants operating lease cost million cash paid amounts included measurement operating lease liabilities million operating lease assets obtained exchange lease obligations million table contents supplemental balance sheet information related operating leases follows december assets assets liabilities accrued current liabilities noncurrent liabilities weightedaverage remaining lease term years weightedaverage discount rate includes prepaid leases related lease liability maturities operating leases liabilities follows thereafter total lease payments less imputed interest december company entered additional real estate operating leases yet commenced obligations associated leases total million million relates lease commence april lease term years december prior adoption asc minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters opinion company unlikely resolution matters material companys financial condition results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable table contents companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases pending merck either federal state court plaintiffs vast majority cases generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax federal cases involving allegations femur fractures transferred multidistrict litigation district new jersey femur fracture mdl bellwether case tried date femur fracture mdl glynn v merck jury returned verdict mercks favor addition june femur fracture mdl court granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law august femur fracture mdl court entered order requiring plaintiffs femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case pursuant show cause order march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealed decision us court appeals third circuit third circuit march third circuit issued decision reversing femur fracture mdl courts preemption ruling remanding appealed cases back femur fracture mdl court merck filed petition writ certiorari us supreme court august seeking review third circuits decision supreme court granted mercks petition june may supreme court issued opinion decided third circuit incorrectly concluded issue preemption resolved jury accordingly vacated judgment third circuit remanded proceedings back third circuit address issue manner consistent supreme courts opinion november third circuit remanded cases back district court order allow court determine first instance whether plaintiffs state law claims preempted federal law standards described supreme court opinion december district court ordered merck serve opening brief february plaintiffs file responsive brief april merck may file reply may accordingly december approximately cases actively pending femur fracture mdl december approximately cases alleging femur fractures filed new jersey state court pending judge james hyland middlesex county parties selected initial group cases reviewed fact discovery merck continued select additional cases reviewed december approximately cases alleging femur fractures filed pending california state court femur fracture cases filed california state court coordinated single judge orange county california additionally four femur fracture cases pending state courts discovery presently stayed femur fracture mdl state court california merck intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december merck aware approximately product users alleging januvia andor janumet caused development pancreatic cancer injuries table contents claims filed multidistrict litigation us district court southern district california mdl outside mdl majority claims filed coordinated proceedings superior court california county los angeles california state court november mdl california state courtin separate opinionsgranted summary judgment defendants grounds federal preemption plaintiffs appealed forums november us court appeals ninth circuit vacated judgment remanded discovery november california state appellate court reversed remanded similar grounds march parties mdl california coordinated proceeding agreed coordinate adopt schedule completing discovery general causation preemption issues renewing summary judgment daubert motions stipulated case management schedule hearings daubert summary judgment motions expected take place june december six product users claims pending merck state courts california including illinois june illinois trial court denied mercks motion summary judgment based federal preemption merck appealed illinois appellate court affirmed december merck filed petition leave appeal illinois supreme court february april illinois supreme court stayed consideration pending petition appeal us supreme court issued opinion merck sharp dohme corp v albrecht relating fosamax matter discussed merck filed opinion albrecht illinois supreme court june petition leave appeal decided september illinois supreme court directed intermediate appellate court reconsider earlier ruling illinois appellate court issued favorable decision concluding consistent albrecht preemption presents legal question resolved court addition claims noted company agreed toll statute limitations approximately additional claims company intends continue defending lawsuits vioxx previously disclosed merck defendant lawsuit brought attorney general utah alleging merck misrepresented safety vioxx lawsuit pending utah state court utah seeks damages penalties utah false claims act bench trial matter currently scheduled april governmental proceedings previously disclosed fall company received records subpoena us attorneys office district vermont vt usao pursuant section health insurance portability accountability act hipaa relating investigation potential health care offenses subpoena sought information relating actual potential business relationship arrangement merck practice fusion inc pfi cloudbased electronic health records ehr company acquired allscripts january company cooperated government responded subpoena subsequently may merck received second records subpoena vt usao broadened governments information request seeking information relating mercks relationship ehr company shortly thereafter vt usao served civil investigation demand cid upon merck similarly seeking information companys relationships ehr vendors cid explains government conducting false claims act investigation concerning whether merck andor pfi submitted claims federal healthcare programs violate federal antikickback statute merck cooperating governments investigation previously disclosed april merck received set investigative interrogatories california attorney generals office pursuant investigation conduct agreements allegedly affected delayed competition lantus insulin market interrogatories seek information concerning mercks development insulin glargine product subsequent termination well mercks patent litigation sanofi sa concerning lantus resolution litigation merck cooperating california attorney generals investigation previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may table contents related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate previously disclosed time time company receives inquiries subject preliminary investigation activities competition governmental authorities markets outside united states authorities may include regulators administrative authorities law enforcement similar officials preliminary investigation activities may include site visits formal informal requests demands documents materials inquiries interviews similar matters certain preliminary inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required commercial litigation zetia antitrust litigation previously disclosed merck msd schering corporation msp singapore company llc collectively merck defendants defendants putative class action optout lawsuits filed behalf direct indirect purchasers zetia alleging violations federal state antitrust laws well state statutory common law causes action cases consolidated pretrial purposes federal multidistrict litigation judge rebecca beach smith eastern district virginia december court denied merck defendants motions dismiss stay direct purchaser putative class actions pending bilateral arbitration august district court adopted full report recommendation magistrate judge respect merck defendants motions dismiss nonarbitration issues thereby granting part denying part merck defendants motions dismiss addition june representatives putative direct purchaser class filed amended complaint august retailer optout plaintiffs filed amended complaint merck defendants moved dismiss new allegations complaints october magistrate judge issued report recommendation recommending district judge grant motions entirety december district court adopted report recommendation part district court granted merck defendants motion dismiss extent motion sought dismissal claims overcharges paid entities purchased generic ezetimibe par pharmaceutical inc par pharmaceutical dismissed claims overcharges trial currently scheduled begin october rotavirus vaccines antitrust litigation previously disclosed msd defendant putative class action lawsuits filed behalf direct purchasers rotateq alleging violations federal antitrust laws cases consolidated eastern district pennsylvania january court denied msds motions compel arbitration dismiss consolidated complaint february msd appealed courts order arbitration third circuit october third circuit vacated district courts order remanded limited discovery issue arbitrability msd may file renewed motion compel arbitration sales force litigation previously disclosed may ms kelli smith filed complaint company us district court district new jersey behalf putative class female sales representatives putative subclass female sales representatives children claiming discriminatory policies practices selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination laws april magistrate judge granted plaintiffs request amend complaint add following company subsidiary corporate defendant ii erisa claim iii individual constructive discharge claim one named plaintiffs approximately individuals optedin action optin period closed august plaintiffs filed motion certify title vii pay discrimination class also sought final collective action certification plaintiffs equal pay act claim october parties entered agreement fully resolve smith sales force litigation part settlement exchange full general release individual class claims company agreed pay million december court approved settlement table contents qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending antitrust suit result false claims act suit antitrust suits proceeded discovery complete parties filed briefed cross motions summary judgment currently pending court company continues defend lawsuits merck kgaa litigation previously disclosed january protect longestablished brand rights united states company filed lawsuit merck kgaa darmstadt germany kgaa historically operating emd group united states alleging improperly uses name merck united states kgaa filed suit company france uk germany switzerland mexico india australia singapore hong kong china alleging among things unfair competition trademark infringement andor corporate name infringement uk australia singapore hong kong india kgaa also alleges breach parties coexistence agreement litigation ongoing united states trial date set also ongoing numerous jurisdictions outside united states company defending suits jurisdiction patent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications ndas us food drug administration fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges januvia janumet janumet xr february par pharmaceutical filed suit company us district court district new jersey seeking declaratory judgment invalidity patent owned company covering certain salt polymorphic forms sitagliptin expires response company filed patent infringement lawsuit us district court district delaware par pharmaceutical additional companies also indicated intent market generic versions januvia janumet janumet xr following expiration key patent protection prior expiration latergranted patent owned company covering certain salt polymorphic forms sitagliptin expires later granted patent owned company covering janumet formulation expires par pharmaceutical dismissed case us district court district new jersey company litigate action us district court district delaware company filed patent infringement lawsuit mylan pharmaceuticals inc mylan inc mylan northern district west virginia judicial panel multidistrict litigation entered order transferring companys lawsuit mylan us district court district delaware coordinated consolidated pretrial proceedings cases pending district us district court district delaware scheduled lawsuits single day trial invalidity issues october court schedule separate day trials infringement issues necessary october mylan filed petition inter partes review ipr united states patent trademark office table contents uspto seeking invalidity patent uspto six months filing determine whether institute requested ipr proceeding litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial condition results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial condition results operations liquidity company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year table contents equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans october company entered accelerated share repurchase asr agreements two thirdparty financial institutions dealers asr agreements merck agreed purchase billion mercks common stock total initial delivery million shares mercks common stock based thencurrent market price made dealers merck payments billion made merck dealers october funded existing cash investments well shortterm borrowings payments dealers recorded reductions shareholders equity consisting billion increase treasury stock reflected value initial million shares received october billion decrease otherpaidin capital reflected value stock held back dealers pending final settlement upon settlement asr agreements april merck received additional million shares determined average daily volume weightedaverage price mercks common stock term asr program less negotiated discount bringing total shares received merck program million sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period subject terms applicable awards psu awards generally vest three years prior rsu awards generally vested three years beginning awards granted rsu awards generally vest onethird year threeyear period total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively table contents company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree interest rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december table contents december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plans consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets amortization unrecognized prior service cost net loss amortization termination benefits curtailments settlements net periodic benefit cost credit changes net periodic benefit cost credit year year pension plans largely attributable changes discount rate affecting net loss amortization connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans settlements recorded certain us international pension plans reflected table components net periodic benefit cost credit service cost component included income expense net see note exception certain amounts termination benefits curtailments settlements recorded restructuring costs event giving rise termination benefits curtailment settlement related restructuring actions noted table contents obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities actuarial losses gains primarily reflect changes discount rates december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately respectively companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total us pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments plan assets fair value international pension plans assets cash cash equivalents investment funds developed markets equities government agency obligations emerging markets equities corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns table contents target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions expected contributions approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net loss gain arising period prior service cost credit arising period net loss amortization included benefit cost prior service credit amortization included benefit cost table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate interest crediting rate benefit obligation discount rate salary growth rate interest crediting rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis expected rate return plan developed considering longterm historical returns data current market conditions actual returns plan assets using reference information longterm return expectations asset category weightedaverage expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range decrease reflects lower expected asset returns modest shift asset allocation change weightedaverage expected return us pension postretirement benefit plan assets due relative weighting referenced plans assets health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses gains income investments equity securities net net periodic defined benefit plan credit cost service cost net includes net realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds net presented table includes million goodwill impairment charges related certain businesses healthcare services segment see note net includes gain million related settlement certain patent litigation income million related astrazenecas option exercise connection termination companys relationship astrazeneca lp azlp gain million resulting receipt milestone payment outlicensed migraine clinical development program net also includes million goodwill impairment charges related certain businesses healthcare services segment see note well million charges related writedown assets held sale fair value anticipation dissolution companys joint venture supera farma laboratorios sa brazil net includes income million related astrazenecas option exercise million loss extinguishment debt interest paid million million million taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings gilti foreignderived intangible income deduction tax settlements rd tax credit state taxes acquisition peloton tcja valuation allowances acquisitionrelated costs including amortization restructuring includes tax effects losses foreign subsidiaries miscellaneous items table contents tax cuts jobs act tcja enacted december among provisions tcja reduced us federal corporate statutory tax rate effective january required companies pay onetime transition tax undistributed earnings certain foreign subsidiaries created new taxes certain foreign sourced earnings company reflected impact tcja financial statements however since application certain provisions tcja remained subject interpretation certain instances company made reasonable estimates effects tcja since finalized described onetime transition tax based companys post undistributed earnings profits ep substantial portion undistributed ep company previously provided deferred taxes earnings deemed merck retained indefinitely subsidiary companies reinvestment company recorded provisional amount onetime transition tax liability billion provisional amount reduced reversal billion deferred taxes previously recorded connection merger scheringplough corporation certain undistributed foreign ep basis revised calculations post undistributed foreign ep finalization amounts held cash specified assets company recognized measurementperiod adjustment million related transition tax obligation corresponding adjustment income tax expense period resulting revised transition tax obligation billion company recorded additional charges million related finalization treasury regulations associated tcja permitted tcja company elected pay onetime transition tax period eight years companys remaining transition tax liability reduced payments utilization foreign tax credits billion december million included income taxes payable remainder billion included noncurrent liabilities company remeasured deferred tax assets liabilities new federal statutory tax rate resulted provisional deferred tax benefit million basis clarifications deferred tax benefit calculation company recorded measurementperiod adjustments million related deferred income taxes foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly ireland switzerland well singapore puerto rico operate tax incentive grants begin expire earnings indefinitely reinvested thereby yielding favorable impact effective tax rate compared us statutory rate foreign earnings tax rate differentials include impact intangible asset impairment charges amortization purchase accounting adjustments restructuring costs items presented separately represent significant separately disclosed pretax cost charge substantial portion items relates jurisdictions lower tax rates united states therefore impact recording expense items lower tax rate jurisdictions unfavorable impact effective tax rate compared us statutory rate income taxes consisted years ended december domestic foreign table contents taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities product intangibles licenses inventory related accelerated depreciation pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred taxes nol carryforwards relate foreign jurisdictions valuation allowances billion established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards expected fully utilized prior expiry income taxes paid billion billion billion respectively tax benefits relating stock option exercises million million million reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflect settlements irs discussed amount includes million related divestiture mercks consumer care business table contents company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease approximately million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures interest penalties associated uncertain tax positions amounted benefit expense million million million amounts reflect beneficial impacts various tax settlements including discussed liabilities accrued interest penalties million million december respectively internal revenue service irs concluded examinations mercks us federal income tax returns result company required make payment million companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded million net tax benefit net benefit reflects reductions reserves unrecognized tax benefits tax positions relating years examination partially offset additional reserves tax positions previously reserved irs concluded examinations mercks us federal income tax returns result company required make payment approximately billion companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded net million tax benefit net benefit reflects reductions reserves unrecognized tax benefits tax positions relating years examination partially offset additional reserves tax positions previously reserved well adjustments reserves unrecognized tax benefits relating years remain open examination affected settlement irs currently conducting examinations companys tax returns years addition various state foreign tax examinations progress jurisdictions companys income tax returns open examination period earnings per share calculations earnings per share shares millions follows years ended december net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes adoption asu adoption asu balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains losses sales availableforsale investments reclassified aoci income expense net amounts included investments debt equity securities however result adoption asu amounts relate investments availableforsale debt securities includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles result changes companys internal reporting structure certain costs previously included pharmaceutical segment included part nonsegment expenses within merck research laboratories prior period pharmaceutical segment profits recast reflect changes comparable basis animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients company recently sold certain businesses healthcare services segment process divesting remaining businesses alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded table contents sales companys products follows years ended december us intl total us intl total us intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima emend vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq vaqta hospital acute care bridion noxafil primaxin invanz cubicin cancidas immunology simponi remicade neuroscience belsomra virology isentressisentress hd zepatier cardiovascular zetia vytorin atozet adempas diabetes januvia janumet womens health nuvaring implanonnexplanon diversified brands singulair cozaarhyzaar nasonex arcoxia follistim aq pharmaceutical total pharmaceutical segment sales animal health livestock companion animals total animal health segment sales segment sales total segment sales us plus international may equal total due rounding alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments healthcare services alliances primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales also includes approximately million million million respectively related sale marketing rights certain products table contents consolidated sales geographic area derived follows years ended december united states europe middle east africa japan china asia pacific japan china latin america reconciliation segment profits income taxes follows years ended december segment profits pharmaceutical segment animal health segment segments total segment profits profits unallocated interest income interest expense depreciation amortization research development amortization purchase accounting adjustments restructuring costs charge related termination collaboration samsung loss extinguishment debt unallocated net income taxes pharmaceutical segment profits comprised segment sales less standard costs well selling general administrative expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well selling general administrative expenses research development costs directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred merck research laboratories companys research development division focuses human healthrelated activities general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales unallocated net includes expenses corporate manufacturing cost centers goodwill intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value liabilities contingent consideration miscellaneous income expense items table contents equity income loss affiliates depreciation amortization included segment profits follows pharmaceutical animal health total year ended december included segment profits equity income loss affiliates depreciation amortization year ended december included segment profits equity income loss affiliates depreciation amortization year ended december included segment profits equity income loss affiliates depreciation amortization property plant equipment net geographic area located follows december united states europe middle east africa asia pacific japan china latin america china japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors stockholders merck co inc opinions financial statements internal control financial reporting audited accompanying consolidated balance sheet merck co inc subsidiaries company december related consolidated statements income comprehensive income equity cash flows three years period ended december including related notes collectively referred consolidated financial statements also audited companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions companys management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report internal control financial reporting appearing item responsibility express opinions companys consolidated financial statements companys internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable table contents assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate critical audit matters critical audit matter communicated matter arising current period audit consolidated financial statements communicated required communicated audit committee relates accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matter providing separate opinion critical audit matter accounts disclosures relates customer discount accruals us medicaid managed care medicare part rebates described note consolidated financial statements company records certain variable consideration including discounts estimated time sale generally using expected value method amounts accrued aggregate customer discounts december us billion evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued certain discounts take form rebates amounts owed based upon definitive contractual agreements legal requirements private sector managed care public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers management uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision principal considerations determination performing procedures relating customer discount accruals us medicaid managed care medicare part rebates critical audit matter significant judgment required management significant measurement uncertainty calculation rebate accruals includes assumptions related price customer segment utilization pertaining forecasted customer claims may fully paid subsequent period turn led high degree auditor judgment subjectivity effort applying procedures related assumptions addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating customer discount accruals us medicaid managed care medicare part rebates including managements controls assumptions used estimate corresponding rebate accruals procedures also included among others developing independent estimate rebate accruals utilizing third party data customer segment utilization changes price terms specific rebate programs historical trend actual rebate claims paid independent estimate compared rebate accruals recorded management evaluate reasonableness estimate additionally procedures included testing actual rebate claims paid evaluating contractual terms companys rebate agreements pricewaterhousecoopers llp florham park new jersey february served companys auditor since table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales cost sales selling general administrative research development restructuring costs income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders sales cost sales selling general administrative research development restructuring costs income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders amounts include charge related acquisition peloton therapeutics inc see note amounts include charge related formation collaboration eisai see note amounts reflect acquisition divestiturerelated costs see note impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective fourth quarter changes internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued table contents committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier robert davis chairman president executive vice president global services chief executive officer chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act applicable incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website httpwwwmsdcomabouthowwe operatecodeofconductvaluesandstandardshtml company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation benefits committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck co inc incentive stock plans merck co inc nonemployee directors stock option plan excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item